<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00215</drugbank-id>
  <drugbank-id>APRD00147</drugbank-id>
  <name>Citalopram</name>
  <description>Citalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label].  Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label].  This drug was initially approved by the FDA in 1998 [L5230].</description>
  <cas-number>59729-33-8</cas-number>
  <unii>0DHU5B8D6V</unii>
  <average-mass>324.3919</average-mass>
  <monoisotopic-mass>324.163791509</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A321</ref-id>
        <pubmed-id>1424428</pubmed-id>
        <citation>Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992 Nov;52(5):547-52.</citation>
      </article>
      <article>
        <ref-id>A322</ref-id>
        <pubmed-id>12494286</pubmed-id>
        <citation>Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002 Dec;14(6):502-5.</citation>
      </article>
      <article>
        <ref-id>A323</ref-id>
        <pubmed-id>8104273</pubmed-id>
        <citation>Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet. 1993 Oct 2;342(8875):837-9.</citation>
      </article>
      <article>
        <ref-id>A324</ref-id>
        <pubmed-id>16430968</pubmed-id>
        <citation>Clayton A, Keller A, McGarvey EL: Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006 Mar;91(1):27-32. Epub 2006 Jan 20.</citation>
      </article>
      <article>
        <ref-id>A325</ref-id>
        <pubmed-id>8732438</pubmed-id>
        <citation>Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996 Mar;11 Suppl 1:5-11.</citation>
      </article>
      <article>
        <ref-id>A327</ref-id>
        <pubmed-id>9571301</pubmed-id>
        <citation>Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998 Apr;34(4):281-302.</citation>
      </article>
      <article>
        <ref-id>A174382</ref-id>
        <pubmed-id>10863884</pubmed-id>
        <citation>Bezchlibnyk-Butler K, Aleksic I, Kennedy SH: Citalopram--a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000 May;25(3):241-54.</citation>
      </article>
      <article>
        <ref-id>A174388</ref-id>
        <pubmed-id>11206593</pubmed-id>
        <citation>Keller MB: Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry. 2000 Dec;61(12):896-908.</citation>
      </article>
      <article>
        <ref-id>A174394</ref-id>
        <pubmed-id>23018033</pubmed-id>
        <citation>Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL: Considerations on safety concerns about citalopram prescribing. Mayo Clin Proc. 2012 Nov;87(11):1042-5. doi: 10.1016/j.mayocp.2012.07.009. Epub 2012 Sep 24.</citation>
      </article>
      <article>
        <ref-id>A174406</ref-id>
        <pubmed-id>10863887</pubmed-id>
        <citation>Naranjo CA, Knoke DM, Bremner KE: Variations in response to citalopram in men and women with alcohol dependence. J Psychiatry Neurosci. 2000 May;25(3):269-75.</citation>
      </article>
      <article>
        <ref-id>A174409</ref-id>
        <pubmed-id>9466233</pubmed-id>
        <citation>Thomsen PH: Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol. 1997;7(3):157-66. doi: 10.1089/cap.1997.7.157.</citation>
      </article>
      <article>
        <ref-id>A174412</ref-id>
        <pubmed-id>12934982</pubmed-id>
        <citation>McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr: Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry. 2003 Jul;64(7):807-13.</citation>
      </article>
      <article>
        <ref-id>A37688</ref-id>
        <pubmed-id>21546862</pubmed-id>
        <citation>Sangkuhl K, Klein TE, Altman RB: PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72. doi: 10.1097/FPC.0b013e328346063f.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T406</ref-id>
        <isbn/>
        <citation>https://www.ncbi.nlm.nih.gov/books/NBK482222/ (2018). Stat Pearls [Internet]. NIH Stat Pearls.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L1355</ref-id>
        <title>MSDS  citalopram</title>
        <url>https://www.spectrumchemical.com/MSDS/C2408ANSI-C2408AGHS.pdf</url>
      </link>
      <link>
        <ref-id>L5224</ref-id>
        <title>NIH Stat Pearls: Citalopram</title>
        <url>https://www.ncbi.nlm.nih.gov/books/NBK482222/</url>
      </link>
      <link>
        <ref-id>L5227</ref-id>
        <title>AAFP: Off-label Applications for SSRIs</title>
        <url>https://www.aafp.org/afp/2003/0801/p498.html</url>
      </link>
      <link>
        <ref-id>L5230</ref-id>
        <title>Celexa Information, FDA</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F3271</ref-id>
        <title>Celexa Monograph</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/271/original/Celexa_Monograph.pdf?1549042837</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference>Hans Petersen, "Method for the preparation of citalopram." U.S. Patent US6229026, issued December, 1992.</synthesis-reference>
  <indication>For the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412].</indication>
  <pharmacodynamics>Citalopram belongs to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It has been found to relieve or manage symptoms of depression, anxiety, eating disorders and obsessive-compulsive disorder among other mood disorders. The antidepressant, anti-anxiety, and other actions of citalopram are linked to its inhibition of CNS central uptake of serotonin [FDA label]. Serotonergic abnormalities have been reported in patients with mood disorders. Behavioral and neuropsychological of effects of serotonin include the regulation of mood, perception, reward, anger, aggression, appetite, memory, sexuality, and attention, as examples. The onset of action for depression is approximately 1 to 4 weeks. The complete response may take 8-12 weeks after initiation of citalopram [L5224].&#13;
&#13;
 &lt;i&gt;In vitro&lt;/i&gt; studies demonstrate that citalopram is a strong and selective inhibitor of neuronal serotonin reuptake and has weak effects on norepinephrine and dopamine central reuptake. The chronic administration of citalopram has been shown to downregulate central norepinephrine receptors, similar to other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase [A325].</pharmacodynamics>
  <mechanism-of-action>&#13;
The mechanism of action of citalopram results from its inhibition of CNS neuronal reuptake of serotonin (5-HT) [FDA label].  The molecular target for citalopram is the serotonin transporter (solute carrier family 6 member 4, _SLC6A4_), inhibiting its serotonin reuptake in the synaptic cleft [A37688].&#13;
&#13;
Citalopram binds with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs [FDA label]. This drug has no or neglible affinity for _5-HT1A_, _5-HT2A_, _dopamine D_1 and _D2_, _α1-_, _α2_-, and_ β­ adrenergic_, _histamine H1_, _gamma-aminobutyric acid_ (GABA), _muscarinic_,  _cholinergic_, and _benzodiazepine_ receptors. Antagonism of _muscarinic_, _histaminergic_, and _adrenergic receptors_ is thought to be associated with several anticholinergic, sedative, and cardiovascular effects of other psychotropic drugs [FDA label].</mechanism-of-action>
  <toxicity>**Oral (Human) LD**: 56 mg/kg&#13;
**Intraperitoneal (Mouse) LD50**: 179 mg/kg&#13;
&#13;
**Acute toxicity**&#13;
&#13;
Symptoms of toxicity include dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. Rarely, symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and extremely rare cases of cardiac torsade de pointes) may occur. Acute renal failure has been a rare occurrence [A325].&#13;
&#13;
In cases of overdose, establish and maintain the airway to ensure adequate ventilation and oxygen delivery. Due to the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are advised, in addition to supportive care. With the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit [FDA label].&#13;
&#13;
**Pregnancy**&#13;
&#13;
This drug is categorized as pregnancy category C. In animal reproduction studies, citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, which includes teratogenic effects when given at doses higher than human therapeutic doses. There are no sufficient and well-controlled studies in pregnant women; therefore, citalopram should be used during pregnancy only in cases where the potential benefit justifies the possible risk to the fetus [FDA label].&#13;
&#13;
**Pregnancy-Nonteratogenic Effects**&#13;
&#13;
Neonates exposed to celexa and other SSRIs or SNRIs, late in the third trimester, have undergone complications requiring prolonged hospitalization, respiratory support, and parenteral feeding. Complications such as these can arise immediately upon delivery [FDA label]. &#13;
&#13;
**Nursing Mothers**&#13;
&#13;
Citalopram is excreted in human breast milk. There have been two reports of infants demonstrating high levels of somnolence, reduced feeding, and weight loss associated with breastfeeding from a mother taking citalopram. In one specific case, the infant was reported to recover completely after the discontinuation of citalopram.  In the second case, no follow-up information was available for assessment. The decision whether to continue or discontinue either nursing or celexa should consider the risks of citalopram exposure for the infant versus the benefits of celexa treatment for the mother [FDA label].&#13;
&#13;
</toxicity>
  <metabolism>Citalopram is metabolized mainly in the liver via &lt;i&gt;N&lt;/i&gt;-demethylation to its main metabolite, _demethylcitalopram_ by CYP2C19 and CYP3A4 [A174382]. Other metabolites include _didemethylcitalopram_ via CYP2D6 metabolism, and _citalopram &lt;i&gt;N&lt;/i&gt;-oxide_ via monoamine oxidase enzymes and aldehyde oxidase. It is a deaminated propionic acid derivative [A174382]. &#13;
&#13;
After a single dose of citalopram, peak blood concentrations occur at approximately 4 hours [FDA label]. This drug in is found mainly unchanged in the plasma as citalopram. Cytochrome P450 (CYP) 3A4 and 2C19 isozymes appear to be heavily involved in producing _demethylcitalopram_. Demethylcitalopram appears to be further &lt;i&gt;N&lt;/i&gt;-demethylated by CYP2D6 to didemethylcitalopram. Citalopram metabolites exert little pharmacologic activity in comparison to the parent drug and are not likely to contribute to the clinical effect of citalopram [A325].&#13;
</metabolism>
  <absorption>Rapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption [FDA label].</absorption>
  <half-life>About 35 hours [FDA label]. &#13;
&#13;
</half-life>
  <protein-binding>Citalopram, dimethylcitalopram, and didemethylcitalopram are 80% bound to plasma proteins [FDA label].</protein-binding>
  <route-of-elimination>12-23% of an oral dose of citalopram is found unchanged in the urine, while 10% of the dose is found in the faeces [FDA label].</route-of-elimination>
  <volume-of-distribution>12 L/kg [FDA label]&#13;
&#13;
Citalopram is highly lipophilic and likely widely distributed throughout the body, including the blood-brain-barrier. However, its metabolite, _demethylcitalopram_ does not penetrate the blood-brain-barrier well [FDA label].</volume-of-distribution>
  <clearance>The systemic clearance of citalopram is 330 mL/min, with approximately 20% renal clearance [FDA label].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.</description>
    <direct-parent>Phenylbutylamines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Phenylbutylamines</subclass>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Aryl fluorides</alternative-parent>
    <alternative-parent>Dialkyl ethers</alternative-parent>
    <alternative-parent>Fluorobenzenes</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Isocoumarans</alternative-parent>
    <alternative-parent>Nitriles</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Carbonitrile</substituent>
    <substituent>Dialkyl ether</substituent>
    <substituent>Ether</substituent>
    <substituent>Fluorobenzene</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Isocoumaran</substituent>
    <substituent>Nitrile</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Phenylbutylamine</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000027</drugbank-id>
      <name>Citalopram hydrobromide</name>
      <unii>I1E9D14F36</unii>
      <cas-number>59729-32-7</cas-number>
      <inchikey>WIHMBLDNRMIGDW-UHFFFAOYSA-N</inchikey>
      <average-mass>405.304</average-mass>
      <monoisotopic-mass>404.089954188</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Citalopram</synonym>
    <synonym language="latin" coder="inn">Citalopramum</synonym>
    <synonym language="english" coder="">Nitalapram </synonym>
  </synonyms>
  <products>
    <product>
      <name>Abbott-citalopram</name>
      <labeller>Abbott</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02414570</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-17</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abbott-citalopram</name>
      <labeller>Abbott</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02414589</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-12</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abbott-citalopram</name>
      <labeller>Abbott</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02414597</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-12</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Accel-citalopram Tablets</name>
      <labeller>Accel Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02355248</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Accel-citalopram Tablets</name>
      <labeller>Accel Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02355256</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Accel-citalopram Tablets</name>
      <labeller>Accel Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02355264</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Citalopram</name>
      <labeller>Sunovion</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248050</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Citalopram</name>
      <labeller>Sunovion</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248051</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Citalopram</name>
      <labeller>Sunovion</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02295431</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-citalopram</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02339390</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-citalopram</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02339404</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-citalopram</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374617</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-citalopram</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246056</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-citalopram</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246057</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-citalopram</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02275562</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-citalopram</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02275570</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-citalopram</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02364255</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-23</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bio-citalopram</name>
      <labeller>Biomed Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02448475</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bio-citalopram</name>
      <labeller>Biomed Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02448491</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bio-citalopram</name>
      <labeller>Biomed Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02448513</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ccp-citalopram</name>
      <labeller>Cellchem Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459914</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ccp-citalopram</name>
      <labeller>Cellchem Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459922</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4985</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-09-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-046</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-17</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>FOREST PHARMACEUTICALS, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0456-4130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-16</started-marketing-on>
      <ended-marketing-on>2007-11-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0456-4010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0456-4020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0456-4040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Celexa 10 mg</name>
      <labeller>Lundbeck Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239606</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Celexa 20 mg</name>
      <labeller>Lundbeck Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239607</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Celexa 40 mg</name>
      <labeller>Lundbeck Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239608</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0227</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0647</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-773</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Red Pharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-0683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-149</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5275</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-066</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1921</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-29</started-marketing-on>
      <ended-marketing-on>2006-11-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077039</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-29</started-marketing-on>
      <ended-marketing-on>2006-11-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077039</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-1924</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-29</started-marketing-on>
      <ended-marketing-on>2006-11-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077039</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>International Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54458-917</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-15</started-marketing-on>
      <ended-marketing-on>2011-08-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-445</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-4521</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-02</started-marketing-on>
      <ended-marketing-on>2011-05-03</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-4522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-02</started-marketing-on>
      <ended-marketing-on>2011-05-03</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-4523</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-02</started-marketing-on>
      <ended-marketing-on>2011-05-03</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-6510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-6512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-455</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aphena Pharma Solutions New Jersey, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53401-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aphena Pharma Solutions New Jersey, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53401-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aphena Pharma Solutions New Jersey, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53401-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0917</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-6511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Greenstone, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>59762-4800</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2014-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Greenstone, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>59762-4801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2014-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Greenstone, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>59762-4802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2014-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>New Horizon Rx Group, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58517-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Safecor Health, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>48433-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Ready Meds</labeller>
      <ndc-id/>
      <ndc-product-code>64205-207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0371</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0373</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-1037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077046</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0906</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0976</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-25</started-marketing-on>
      <ended-marketing-on>2015-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-066</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-25</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-1077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-4740</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-22</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-4741</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-22</started-marketing-on>
      <ended-marketing-on>2016-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-4742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-08</started-marketing-on>
      <ended-marketing-on>2016-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-6231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-04</started-marketing-on>
      <ended-marketing-on>2018-06-07</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-182</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-056</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Camber Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>31722-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-5627</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-288</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-953</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-03</started-marketing-on>
      <ended-marketing-on>2016-03-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>70786-0208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-19</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-13</started-marketing-on>
      <ended-marketing-on>2014-11-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-13</started-marketing-on>
      <ended-marketing-on>2014-11-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>53746-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-13</started-marketing-on>
      <ended-marketing-on>2014-11-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-11</started-marketing-on>
      <ended-marketing-on>2017-03-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-731</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-04</started-marketing-on>
      <ended-marketing-on>2016-11-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-517</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-15</started-marketing-on>
      <ended-marketing-on>2014-02-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-4742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-08</started-marketing-on>
      <ended-marketing-on>2017-06-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-1116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2017-06-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6761</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6691</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on>2017-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on>2017-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on>2017-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>International Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>54458-896</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-01</started-marketing-on>
      <ended-marketing-on>2017-03-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-6232</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-27</started-marketing-on>
      <ended-marketing-on>2018-07-09</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0541</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0573</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>PuraCap Laboratories LLC dba Blu Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>24658-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-03</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>PuraCap Laboratories LLC dba Blu Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>24658-141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-03</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>PuraCap Laboratories LLC dba Blu Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>24658-142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-03</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Core Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64720-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-05</started-marketing-on>
      <ended-marketing-on>2011-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Core Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64720-171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-05</started-marketing-on>
      <ended-marketing-on>2011-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Core Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64720-172</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-05</started-marketing-on>
      <ended-marketing-on>2011-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Legacy Pharmaceutical Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68645-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-30</started-marketing-on>
      <ended-marketing-on>2014-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-21</started-marketing-on>
      <ended-marketing-on>2016-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-22</started-marketing-on>
      <ended-marketing-on>2017-06-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1970</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-08</started-marketing-on>
      <ended-marketing-on>2015-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-08</started-marketing-on>
      <ended-marketing-on>2014-09-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6279</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-08</started-marketing-on>
      <ended-marketing-on>2015-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>16252-510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-07</started-marketing-on>
      <ended-marketing-on>2010-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077034</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>16252-511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-07</started-marketing-on>
      <ended-marketing-on>2010-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077034</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>16252-512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-07</started-marketing-on>
      <ended-marketing-on>2010-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077034</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-30</started-marketing-on>
      <ended-marketing-on>2014-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>St. Marys Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-496</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-23</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0893</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Legacy Pharmaceutical Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68645-467</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Legacy Pharmaceutical Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68645-514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8022</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-8266</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-19</started-marketing-on>
      <ended-marketing-on>2014-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-8267</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-19</started-marketing-on>
      <ended-marketing-on>2014-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-8269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-19</started-marketing-on>
      <ended-marketing-on>2013-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-718</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on>2016-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-22</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-01</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-22</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2518</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on>2016-02-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077046</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2519</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on>2016-09-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077046</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on>2016-08-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077046</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-868</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4291</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-02</started-marketing-on>
      <ended-marketing-on>2017-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-0007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-0005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-375</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65682-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-17</started-marketing-on>
      <ended-marketing-on>2008-01-17</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65682-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-17</started-marketing-on>
      <ended-marketing-on>2008-01-17</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0712</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>RedPharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-0753</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49999-789</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-22</started-marketing-on>
      <ended-marketing-on>2014-06-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49999-654</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services-PA</labeller>
      <ndc-id/>
      <ndc-product-code>67046-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services-PA</labeller>
      <ndc-id/>
      <ndc-product-code>67046-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Contract Pharmacy Services-PA</labeller>
      <ndc-id/>
      <ndc-product-code>67046-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Epic Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42806-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Epic Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42806-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Epic Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42806-021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2732</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aphena Pharma Solutions - Tennessee, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43353-778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077043</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0449</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>QPharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>42708-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0561</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Pharmaceutical Associates, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0121-0848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Pharmaceutical Associates, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0121-1696</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/10mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6232</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-737</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-744</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-385</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077289</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-341</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-822</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-823</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Direct_Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-389</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-670</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-679</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-173</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-174</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077045</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>International Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>54458-889</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>International Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>54458-980</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>International Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>54458-981</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cosette Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0713-4740</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cosette Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0713-4741</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cosette Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0713-4742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077048</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-543</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387948</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387956</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387964</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284847</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on>2012-10-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284855</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on>2012-10-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02301822</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02301830</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02301849</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jubilant Generics Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429535</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jubilant Generics Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429543</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jubilant Generics Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429551</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02353660</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02353679</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02445719</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02342766</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02342774</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02430517</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02430541</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02430568</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Watson Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3176</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Watson Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3177</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Watson Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Glenmark Generics, Inc. USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Glenmark Generics, Inc. USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Glenmark Generics, Inc. USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-5273</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-5274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-5275</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0350</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0225</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077044</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0351</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077046</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-055</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-056</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-480</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-24</started-marketing-on>
      <ended-marketing-on>2018-04-18</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077046</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6661</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-24</started-marketing-on>
      <ended-marketing-on>2018-04-18</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077046</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0258-3695</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-17</started-marketing-on>
      <ended-marketing-on>2010-08-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0258-3696</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-17</started-marketing-on>
      <ended-marketing-on>2010-08-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0258-3697</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-17</started-marketing-on>
      <ended-marketing-on>2010-08-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020822</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram hydrobromide</name>
      <labeller>Legacy Pharmaceutical Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68645-282</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-353</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-352</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0671</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-28</started-marketing-on>
      <ended-marketing-on>2012-04-02</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077035</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0672</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2012-04-02</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077035</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-0673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2012-04-02</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077035</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-670</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/301</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-1038</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7831</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7832</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-664</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>International Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54458-922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-07</started-marketing-on>
      <ended-marketing-on>2013-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-543</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-0378</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-15</started-marketing-on>
      <ended-marketing-on>2005-11-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-5626</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>International Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54458-912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-20</started-marketing-on>
      <ended-marketing-on>2016-06-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-480</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Citron Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>57237-148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-055</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Apotheca, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>12634-027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Apotheca, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>12634-023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Apotheca, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>12634-629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2888</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-727</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-25</started-marketing-on>
      <ended-marketing-on>2011-12-20</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-759</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-28</started-marketing-on>
      <ended-marketing-on>2017-01-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-414</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-02</started-marketing-on>
      <ended-marketing-on>2012-02-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-423</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-14</started-marketing-on>
      <ended-marketing-on>2017-03-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-08</started-marketing-on>
      <ended-marketing-on>2011-08-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-425</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-14</started-marketing-on>
      <ended-marketing-on>2014-05-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-12</started-marketing-on>
      <ended-marketing-on>2017-06-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-12</started-marketing-on>
      <ended-marketing-on>2017-06-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3338</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-294</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-08</started-marketing-on>
      <ended-marketing-on>2012-12-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-094</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-697</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-31</started-marketing-on>
      <ended-marketing-on>2015-02-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-383</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-27</started-marketing-on>
      <ended-marketing-on>2016-07-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-1318</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Red Pharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-1186</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-509</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0228-2755</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2006-01-06</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077033</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0228-2756</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2007-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077033</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0228-2757</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on>2007-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077033</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-835</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-11</started-marketing-on>
      <ended-marketing-on>2016-07-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-23</started-marketing-on>
      <ended-marketing-on>2016-06-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on>2018-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2774</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-168</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-16</started-marketing-on>
      <ended-marketing-on>2017-01-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>ALPHAPHARM PTY LTD</labeller>
      <ndc-id/>
      <ndc-product-code>57315-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2013-01-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077668</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>ALPHAPHARM PTY LTD</labeller>
      <ndc-id/>
      <ndc-product-code>57315-085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2013-01-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077668</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>ALPHAPHARM PTY LTD</labeller>
      <ndc-id/>
      <ndc-product-code>57315-086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2013-01-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077668</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>ALPHAPHARM PTY LTD</labeller>
      <ndc-id/>
      <ndc-product-code>57315-063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2013-01-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077037</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>ALPHAPHARM PTY LTD</labeller>
      <ndc-id/>
      <ndc-product-code>57315-061</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2013-01-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077037</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>ALPHAPHARM PTY LTD</labeller>
      <ndc-id/>
      <ndc-product-code>57315-062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2013-01-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077037</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-26</started-marketing-on>
      <ended-marketing-on>2011-04-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-192</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-20</started-marketing-on>
      <ended-marketing-on>2011-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-589</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71610-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-883</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on>2018-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-249</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on>2018-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-221</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-29</started-marketing-on>
      <ended-marketing-on>2018-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077032</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0377</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0480</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-2359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>St Marys Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>St Marys Medical Park Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>60760-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54838-540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-342</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-344</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0892</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0542</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-2198</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Atlantic Biologicals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-481</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Clinical Solutions Wholesale, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3349</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5895</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1906</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-0802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-8962</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Legacy Pharmaceutical Packaging, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68645-569</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Legacy Pharmaceutical Packaging, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68645-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Legacy Pharmaceutical Packaging, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68645-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Exelan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Exelan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-628</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Exelan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Exelan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Exelan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077534</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Quality Care Products, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-787</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-074</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on>2017-12-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6789</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-8167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>QPharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>42708-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1699</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1917</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3384</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201450</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-5132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Hydrobromide</name>
      <labeller>Legacy Pharmaceutical Packaging, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68645-559</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078216</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Citalopram Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02331950</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02331977</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram Tablets USP</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02353636</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram Tablets USP</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02353644</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram Tablets USP</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02353652</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram-10</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02325047</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram-20</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02257513</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram-40</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02257521</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram-odan</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306239</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-08</started-marketing-on>
      <ended-marketing-on>2015-11-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citalopram-odan</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306247</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-08</started-marketing-on>
      <ended-marketing-on>2015-11-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ctp 30</name>
      <labeller>Sunovion</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296152</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-citalopram</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248942</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-citalopram</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248943</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-citalopram</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02273055</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ecl-citalopram</name>
      <labeller>Ecl Pharma Group Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421739</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ecl-citalopram</name>
      <labeller>Ecl Pharma Group Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421747</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ecl-citalopram</name>
      <labeller>Ecl Pharma Group Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421755</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-citalopram</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302535</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-citalopram</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302543</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-citalopram</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02369664</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-citalopram</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02313405</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-citalopram</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02313413</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-citalopram</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02370085</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>M-citalopram</name>
      <labeller>Mantra Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02467836</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>M-citalopram</name>
      <labeller>Mantra Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02467844</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Manda-citalopram</name>
      <labeller>Manda Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02373971</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on>2013-08-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Manda-citalopram</name>
      <labeller>Manda Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02373998</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on>2013-08-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Manda-citalopram</name>
      <labeller>Manda Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374005</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-03</started-marketing-on>
      <ended-marketing-on>2013-08-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-citalopram</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371871</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-citalopram</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371898</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-citalopram</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371901</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-citalopram</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304686</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-10</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-citalopram</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304694</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-10</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-citalopram</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02370077</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-13</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-citalopram</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429691</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-citalopram</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429705</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-citalopram</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429713</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246594</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-19</started-marketing-on>
      <ended-marketing-on>2018-07-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246595</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-19</started-marketing-on>
      <ended-marketing-on>2018-07-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-citalopram</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246593</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nat-citalopram</name>
      <labeller>Natco Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02409011</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nat-citalopram</name>
      <labeller>Natco Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02409038</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nat-citalopram</name>
      <labeller>Natco Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02409003</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nat-citalopram Tablets</name>
      <labeller>Natco Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443880</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nat-citalopram Tablets</name>
      <labeller>Natco Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443899</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ng Citalopram</name>
      <labeller>Next Generation Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322781</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-14</started-marketing-on>
      <ended-marketing-on>2011-08-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ng Citalopram</name>
      <labeller>Next Generation Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322803</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-14</started-marketing-on>
      <ended-marketing-on>2011-08-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-citalopram</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251558</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-08-27</started-marketing-on>
      <ended-marketing-on>2011-11-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-citalopram</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02251566</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-08-27</started-marketing-on>
      <ended-marketing-on>2011-11-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nra-citalopram</name>
      <labeller>Nora Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02477637</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nra-citalopram</name>
      <labeller>Nora Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02477645</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nra-citalopram</name>
      <labeller>Nora Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02477653</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02360292</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02360306</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02360314</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-citalopram</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248996</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-citalopram</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248997</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pendo-citalopram</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Perrigo Citalopram</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Perrigo Citalopram</name>
      <labeller>Perrigo New York Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>45802-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-18</started-marketing-on>
      <ended-marketing-on>2011-11-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Perrigo Citalopram</name>
      <labeller>Perrigo New York Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>45802-616</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-18</started-marketing-on>
      <ended-marketing-on>2011-07-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Perrigo Citalopram</name>
      <labeller>Perrigo New York Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>45802-596</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-18</started-marketing-on>
      <ended-marketing-on>2011-11-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077042</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PHL-citalopram</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248944</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-06</started-marketing-on>
      <ended-marketing-on>2004-04-06</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-citalopram</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248945</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-06</started-marketing-on>
      <ended-marketing-on>2004-04-06</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-citalopram</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02273543</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-13</started-marketing-on>
      <ended-marketing-on>2006-03-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-citalopram</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248010</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-citalopram</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248011</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-citalopram</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270609</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Priva-citalopram</name>
      <labeller>Pharmapar Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02440245</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Priva-citalopram</name>
      <labeller>Pharmapar Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02440237</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Priva-citalopram</name>
      <labeller>Pharmapar Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02440253</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-citalopram</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02338777</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-24</started-marketing-on>
      <ended-marketing-on>2015-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-citalopram</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02338769</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-citalopram</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02338785</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-citalo</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02285622</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-citalo</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02285630</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-citalopram</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02268000</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-07-14</started-marketing-on>
      <ended-marketing-on>2010-08-06</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-citalopram</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02268019</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-07-14</started-marketing-on>
      <ended-marketing-on>2010-08-06</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252112</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-26</started-marketing-on>
      <ended-marketing-on>2012-12-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252120</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-26</started-marketing-on>
      <ended-marketing-on>2012-12-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-citalopram</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303256</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-citalopram</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303264</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-citalopram</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303272</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-citalopram</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249278</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-24</started-marketing-on>
      <ended-marketing-on>2014-07-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-citalopram</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249286</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-24</started-marketing-on>
      <ended-marketing-on>2013-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-citalopram</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249251</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Citalopram</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248170</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Citalopram</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248171</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sentralopram AM-10</name>
      <labeller>Physician Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code>68405-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Septa-citalopram</name>
      <labeller>Septa Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02355272</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Septa-citalopram</name>
      <labeller>Septa Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02355280</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Septa-citalopram</name>
      <labeller>Septa Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02431629</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sig-citalopram</name>
      <labeller>Sigmacon Lifesciences Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02323710</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sig-citalopram</name>
      <labeller>Sigmacon Lifesciences Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02323729</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02293218</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02293226</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-citalopram</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312336</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-citalopram</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02438739</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-01</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-citalopram</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02438747</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-01</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-citalopram</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02438755</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-01</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Akarin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Celapram</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Ciazil</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Cilift</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Cipram</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Cipramil</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Ciprapine</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Citabax</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Citadur</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Citalec</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Citol</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Citopam</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Citox</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Citrol</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Dalsan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Elopram</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Humorup</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Oropram</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pramcit</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Recital</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Seropram</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Talam</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Talohexal</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Temperax</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Vodelax</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Zentius</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Zetalo</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Perrigo Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Sentralopram AM-10</name>
      <ingredients>Choline + Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Perrigo Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Perrigo Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Perrigo Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Hydrobromide</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa 20 mg</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa 40 mg</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Apo-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Apo-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>PMS-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>PMS-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Act Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Act Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Dom-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Dom-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram-20</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram-40</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>PMS-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Dom-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Auro-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Auro-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ran-citalo</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ran-citalo</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Teva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Teva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ctp 30</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Riva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Riva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Riva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Teva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram-10</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Accel-citalopram Tablets</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Accel-citalopram Tablets</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Accel-citalopram Tablets</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Septa-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Septa-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mar-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mar-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mar-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Riva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Riva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Novo-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Novo-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ran-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ran-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ng Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ng Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Q-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ava-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Manda-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Manda-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Manda-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Celexa 10 mg</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Act Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Tablets</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Tablets</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Tablets USP</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Tablets USP</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram Tablets USP</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Pendo-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Q-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Q-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mint-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mint-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mint-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram-odan</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram-odan</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nat-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nat-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Abbott-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Abbott-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Abbott-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Riva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nat-citalopram Tablets</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nat-citalopram Tablets</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mint-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mint-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Mint-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Septa-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Priva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ccp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ccp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>M-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>M-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ag-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ag-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ag-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>PHL-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>PHL-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>PHL-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Van-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Van-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Van-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Priva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Priva-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Bio-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Bio-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Bio-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nat-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nu-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nu-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ecl-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ecl-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Ecl-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nra-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nra-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Nra-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Sig-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
    <mixture>
      <name>Sig-citalopram</name>
      <ingredients>Citalopram</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Actavis Group</name>
      <url>http://www.actavis.com</url>
    </packager>
    <packager>
      <name>Advanced Pharmaceutical Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Aidarex Pharmacuticals LLC</name>
      <url>http://www.aidarex.com</url>
    </packager>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>Amkas Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Amneal Pharmaceuticals</name>
      <url>http://www.amneal.com</url>
    </packager>
    <packager>
      <name>Apotex Inc.</name>
      <url>http://www.apotex.com</url>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Atlantic Biologicals Corporation</name>
      <url>http://www.atlanticbiologicals.com</url>
    </packager>
    <packager>
      <name>Aurobindo Pharma Ltd.</name>
      <url>http://www.aurobindo.com</url>
    </packager>
    <packager>
      <name>Aurolife Pharma LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Blu Pharmaceuticals LLC</name>
      <url>http://www.blurx.us</url>
    </packager>
    <packager>
      <name>Bryant Ranch Prepack</name>
      <url>http://bryantranchprepack.com</url>
    </packager>
    <packager>
      <name>Camber Pharmaceuticals Inc.</name>
      <url>http://www.camberpharma.com</url>
    </packager>
    <packager>
      <name>Caraco Pharmaceutical Labs</name>
      <url>http://www.caraco.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Cipla Ltd.</name>
      <url>http://www.cipla.com</url>
    </packager>
    <packager>
      <name>Cobalt Pharmaceuticals Inc.</name>
      <url>http://www.cobaltpharma.com</url>
    </packager>
    <packager>
      <name>Comprehensive Consultant Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Corepharma LLC</name>
      <url>http://www.corepharma.com</url>
    </packager>
    <packager>
      <name>Coupler Enterprises Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Cypress Pharmaceutical Inc.</name>
      <url>http://www.cypressrx.com</url>
    </packager>
    <packager>
      <name>Dept Health Central Pharmacy</name>
      <url/>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>Doctor Reddys Laboratories Ltd.</name>
      <url>http://www.drreddys.com</url>
    </packager>
    <packager>
      <name>Eon Labs</name>
      <url/>
    </packager>
    <packager>
      <name>Forest Laboratories Inc.</name>
      <url>http://www.frx.com</url>
    </packager>
    <packager>
      <name>Forest Pharmaceuticals</name>
      <url>http://www.forestpharm.com</url>
    </packager>
    <packager>
      <name>Glenmark Generics Ltd.</name>
      <url>http://www.glenmark-generics.com</url>
    </packager>
    <packager>
      <name>Greenstone LLC</name>
      <url>http://www.greenstonellc.com</url>
    </packager>
    <packager>
      <name>Heartland Repack Services LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Innoviant Pharmacy Inc.</name>
      <url>http://www.innoviantpharmacy.com</url>
    </packager>
    <packager>
      <name>International Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>InvaGen Pharmaceuticals Inc.</name>
      <url>http://www.invagen.com</url>
    </packager>
    <packager>
      <name>Inwood Labs</name>
      <url>http://www.inwoodlabs.com</url>
    </packager>
    <packager>
      <name>Kali Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Legacy Pharmaceuticals Packaging LLC</name>
      <url>http://www.legacypackaging.com</url>
    </packager>
    <packager>
      <name>Lundbeck Inc.</name>
      <url>http://www.lundbeckinc.com</url>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Matrix Laboratories Ltd.</name>
      <url>http://www.matrixlabsindia.com</url>
    </packager>
    <packager>
      <name>Medvantx Inc.</name>
      <url>http://www.medvantx.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Palmetto Pharmaceuticals Inc.</name>
      <url>http://www.palmettopharm.com</url>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Perrigo Co.</name>
      <url>http://www.perrigo.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Pliva Inc.</name>
      <url>http://www.pliva.com</url>
    </packager>
    <packager>
      <name>Preferred Pharmaceuticals Inc.</name>
      <url>http://www.preferredpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Prepackage Specialists</name>
      <url/>
    </packager>
    <packager>
      <name>Prepak Systems Inc.</name>
      <url>http://www.prepaksys.com</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Remedy Repack</name>
      <url>http://www.remedyrepack.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Roxane Labs</name>
      <url>http://www.roxane.com</url>
    </packager>
    <packager>
      <name>Silarx Pharmaceuticals</name>
      <url>http://www.silarx.com</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Torrent Pharmaceuticals</name>
      <url>http://www.torrentpharma.com</url>
    </packager>
    <packager>
      <name>Va Cmop Dallas</name>
      <url/>
    </packager>
    <packager>
      <name>Vangard Labs Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>W and D Distributing Co.</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="true" url="">Alphapharm party ltd</manufacturer>
    <manufacturer generic="false" url="">Forest laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Apotex inc richmond hill</manufacturer>
    <manufacturer generic="true" url="">Aurobindo pharma ltd inc</manufacturer>
    <manufacturer generic="true" url="">Roxane laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Silarx pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Biovail laboratories international srl</manufacturer>
    <manufacturer generic="true" url="">Actavis elizabeth llc</manufacturer>
    <manufacturer generic="true" url="">Amneal pharmaceuticals ny llc</manufacturer>
    <manufacturer generic="true" url="">Apotex inc etobicoke site</manufacturer>
    <manufacturer generic="true" url="">Aurobindo pharma ltd</manufacturer>
    <manufacturer generic="true" url="">Caraco pharmaceutical laboratories ltd</manufacturer>
    <manufacturer generic="true" url="">Corepharma llc</manufacturer>
    <manufacturer generic="true" url="">Dr reddys laboratories ltd</manufacturer>
    <manufacturer generic="true" url="">Epic pharma llc</manufacturer>
    <manufacturer generic="true" url="">Glenmark generics ltd</manufacturer>
    <manufacturer generic="true" url="">Invagen pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Ivax pharmaceuticals inc sub teva pharmaceuticals usa</manufacturer>
    <manufacturer generic="true" url="">Matrix laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Mutual pharmaceutical co inc</manufacturer>
    <manufacturer generic="true" url="">Mylan pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Natco pharma ltd</manufacturer>
    <manufacturer generic="true" url="">Pliva inc</manufacturer>
    <manufacturer generic="true" url="">Sandoz inc</manufacturer>
    <manufacturer generic="true" url="">Taro pharmaceuticals usa inc</manufacturer>
    <manufacturer generic="true" url="">Teva pharmaceuticals usa</manufacturer>
    <manufacturer generic="true" url="">Torrent pharmaceuticals ltd</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Celexa 20 mg Tablet</description>
      <cost currency="USD">1.47</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Celexa 40 mg Tablet</description>
      <cost currency="USD">1.47</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram hbr 10 mg tablet</description>
      <cost currency="USD">2.33</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram hbr 20 mg tablet</description>
      <cost currency="USD">2.43</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram hbr 40 mg tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram Hydrobromide 10 mg tablet</description>
      <cost currency="USD">2.68</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram Hydrobromide 20 mg tablet</description>
      <cost currency="USD">2.8</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram Hydrobromide 40 mg tablet</description>
      <cost currency="USD">2.89</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Celexa 10 mg tablet</description>
      <cost currency="USD">3.57</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Celexa 20 mg tablet</description>
      <cost currency="USD">3.72</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Celexa 40 mg tablet</description>
      <cost currency="USD">3.88</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram Hydrobromide 10 mg/5ml Solution 240ml Bottle</description>
      <cost currency="USD">122.28</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Pms-Citalopram 10 mg Tablet</description>
      <cost currency="USD">0.47</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram-Odan 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Citalopram-Odan 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Jamp-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Jamp-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mint-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mint-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ng Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ng Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Citalo 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Citalo 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Citalopram 20 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Citalopram 40 mg Tablet</description>
      <cost currency="USD">0.82</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ctp 30 30 mg Tablet</description>
      <cost currency="USD">0.99</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Antidepressive Agents</category>
      <mesh-id>D000928</mesh-id>
    </category>
    <category>
      <category>Antidepressive Agents, Second-Generation</category>
      <mesh-id>D018687</mesh-id>
    </category>
    <category>
      <category>Benzofurans</category>
      <mesh-id>D001572</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Depressants</category>
      <mesh-id>D002492</mesh-id>
    </category>
    <category>
      <category>Combined Inhibitors of Serotonin/Norepinephrine Reuptake</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors</category>
      <mesh-id>D065609</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2B6 Inhibitors</category>
      <mesh-id>D065686</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inhibitors</category>
      <mesh-id>D065689</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Inhibitors</category>
      <mesh-id>D065690</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Highest Risk QTc-Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hypoglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Uptake Inhibitors</category>
      <mesh-id>D014179</mesh-id>
    </category>
    <category>
      <category>Nitriles</category>
      <mesh-id>D009570</mesh-id>
    </category>
    <category>
      <category>P-glycoprotein inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Propylamines</category>
      <mesh-id>D011437</mesh-id>
    </category>
    <category>
      <category>Psychoanaleptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychotropic Drugs</category>
      <mesh-id>D011619</mesh-id>
    </category>
    <category>
      <category>QTc Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Selective Serotonin Reuptake Inhibitors</category>
      <mesh-id>D017367</mesh-id>
    </category>
    <category>
      <category>Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome</category>
      <mesh-id>D020230</mesh-id>
    </category>
    <category>
      <category>Serotonin 5-HT2 Receptor Antagonists</category>
      <mesh-id>D058830</mesh-id>
    </category>
    <category>
      <category>Serotonin Agents</category>
      <mesh-id>D018490</mesh-id>
    </category>
    <category>
      <category>Serotonin Modulators</category>
      <mesh-id/>
    </category>
    <category>
      <category>Serotonin Receptor Antagonists</category>
      <mesh-id>D012702</mesh-id>
    </category>
    <category>
      <category>Vasodilating Agents</category>
      <mesh-id>D014665</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>20 mg/10mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>10 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg/301</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N06AB04">
      <level code="N06AB">Selective serotonin reuptake inhibitors</level>
      <level code="N06A">ANTIDEPRESSANTS</level>
      <level code="N06">PSYCHOANALEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>28:16.04.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00215.pdf?1548977283</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00215.pdf?1549040558</msds>
  <patents>
    <patent>
      <number>2353693</number>
      <country>Canada</country>
      <approved>2003-07-22</approved>
      <expires>2021-07-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2049368</number>
      <country>Canada</country>
      <approved>2001-10-23</approved>
      <expires>2011-08-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
    <food-interaction>Avoid St.John's Wort.</food-interaction>
    <food-interaction>Take without regard to meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>The metabolism of Lomitapide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Zafirlukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08824</drugbank-id>
      <name>Ioflupane I-123</name>
      <description>Citalopram may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Citalopram can be increased when used in combination with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>Nabilone may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>Perampanel may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Citalopram may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>Citalopram may increase the sedative activities of Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The risk or severity of adverse effects can be increased when Rufinamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Eslicarbazepine acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The risk or severity of QTc prolongation and serotonin syndrome can be increased when Fluconazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The metabolism of Eliglustat can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The metabolism of Ibrutinib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08933</drugbank-id>
      <name>Luliconazole</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Luliconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The metabolism of Colchicine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The metabolism of Fentanyl can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The metabolism of Iloperidone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01256</drugbank-id>
      <name>Retapamulin</name>
      <description>The metabolism of Retapamulin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The metabolism of Tofacitinib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The metabolism of Vardenafil can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The metabolism of Zopiclone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Lovastatin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The metabolism of Zolmitriptan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The risk or severity of adverse effects can be increased when Methadone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The metabolism of Alfuzosin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The metabolism of Alprazolam can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The serum concentration of Acenocoumarol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The serum concentration of (R)-warfarin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08735</drugbank-id>
      <name>R,S-Warfarin alcohol</name>
      <description>The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08736</drugbank-id>
      <name>S,R-Warfarin alcohol</name>
      <description>The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The serum concentration of (S)-Warfarin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Tacrolimus can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Citalopram can be decreased when it is combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Atorvastatin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Citalopram may increase the serotonergic activities of Mirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Morphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Codeine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Dihydroetorphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Desomorphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The risk or severity of serotonin syndrome can be increased when Carfentanil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The risk or severity of serotonin syndrome can be increased when Alphacetylmethadol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The risk or severity of serotonin syndrome can be increased when Lofentanil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The risk or severity of serotonin syndrome can be increased when Opium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Carfentanil, C-11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Naltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Bezitramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Eluxadoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Nicomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Benzhydrocodone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06704</drugbank-id>
      <name>Iobenguane</name>
      <description>Citalopram may decrease effectiveness of Iobenguane as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Benzthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The risk or severity of hyponatremia can be increased when Citalopram is combined with Epitizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of adverse effects can be increased when Baclofen is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00189</drugbank-id>
      <name>Ethchlorvynol</name>
      <description>The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Succinylcholine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The risk or severity of adverse effects can be increased when Enflurane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The risk or severity of adverse effects can be increased when Butalbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The risk or severity of adverse effects can be increased when Talbutal is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>The risk or severity of adverse effects can be increased when Palonosetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00423</drugbank-id>
      <name>Methocarbamol</name>
      <description>The risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The risk or severity of adverse effects can be increased when Metharbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The risk or severity of adverse effects can be increased when Methohexital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The risk or severity of adverse effects can be increased when Cisatracurium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00579</drugbank-id>
      <name>Mazindol</name>
      <description>The risk or severity of adverse effects can be increased when Mazindol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The risk or severity of adverse effects can be increased when Lisuride is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The risk or severity of adverse effects can be increased when Paramethadione is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>The risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00662</drugbank-id>
      <name>Trimethobenzamide</name>
      <description>The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The risk or severity of adverse effects can be increased when Rocuronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>The risk or severity of adverse effects can be increased when Meclizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The risk or severity of adverse effects can be increased when Riluzole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The risk or severity of adverse effects can be increased when Clidinium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The risk or severity of adverse effects can be increased when Propiomazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Acetazolamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The risk or severity of adverse effects can be increased when Phensuximide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzphetamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Alprenolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The risk or severity of adverse effects can be increased when Almotriptan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The risk or severity of adverse effects can be increased when Hexafluronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of adverse effects can be increased when Naratriptan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of adverse effects can be increased when Pindolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The risk or severity of adverse effects can be increased when Alosetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The risk or severity of adverse effects can be increased when Ramelteon is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Frovatriptan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The risk or severity of adverse effects can be increased when Guanfacine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>The risk or severity of adverse effects can be increased when Acetophenazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The risk or severity of adverse effects can be increased when Melatonin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The risk or severity of adverse effects can be increased when Clonazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The risk or severity of adverse effects can be increased when Vigabatrin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01107</drugbank-id>
      <name>Methyprylon</name>
      <description>The risk or severity of adverse effects can be increased when Methyprylon is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The risk or severity of adverse effects can be increased when Phenacemide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The risk or severity of adverse effects can be increased when Doxacurium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The risk or severity of adverse effects can be increased when Thiamylal is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of adverse effects can be increased when Halothane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The risk or severity of adverse effects can be increased when Pergolide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Tubocurarine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The risk or severity of adverse effects can be increased when Ketamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The risk or severity of adverse effects can be increased when Mivacurium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The risk or severity of adverse effects can be increased when Levodopa is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Decamethonium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The risk or severity of adverse effects can be increased when Ergometrine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The risk or severity of adverse effects can be increased when Metocurine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of adverse effects can be increased when Pancuronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Pipecuronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Vecuronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Amobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Aprobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Butobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Heptabarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Hexobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of adverse effects can be increased when Penbutolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The risk or severity of adverse effects can be increased when Yohimbine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01437</drugbank-id>
      <name>Glutethimide</name>
      <description>The risk or severity of adverse effects can be increased when Glutethimide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>gamma-Hydroxybutyric acid</name>
      <description>The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of adverse effects can be increased when MMDA is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01489</drugbank-id>
      <name>Camazepam</name>
      <description>The risk or severity of adverse effects can be increased when Camazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01495</drugbank-id>
      <name>Dichloralphenazone</name>
      <description>The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01501</drugbank-id>
      <name>Difenoxin</name>
      <description>The risk or severity of adverse effects can be increased when Difenoxin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Delorazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01534</drugbank-id>
      <name>Chlorhexadol</name>
      <description>The risk or severity of adverse effects can be increased when Chlorhexadol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01547</drugbank-id>
      <name>Drotebanol</name>
      <description>The risk or severity of adverse effects can be increased when Drotebanol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01553</drugbank-id>
      <name>Cloxazolam</name>
      <description>The risk or severity of adverse effects can be increased when Cloxazolam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Clotiazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Metamfetamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The risk or severity of adverse effects can be increased when Quazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01594</drugbank-id>
      <name>Cinolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Cinolazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>The risk or severity of adverse effects can be increased when Periciazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01616</drugbank-id>
      <name>Alverine</name>
      <description>The risk or severity of adverse effects can be increased when Alverine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The risk or severity of adverse effects can be increased when Pipotiazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>The risk or severity of adverse effects can be increased when Thioproperazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02234</drugbank-id>
      <name>S-Ethylisothiourea</name>
      <description>The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02852</drugbank-id>
      <name>Domoic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Domoic Acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The risk or severity of adverse effects can be increased when Valpromide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04819</drugbank-id>
      <name>Methapyrilene</name>
      <description>The risk or severity of adverse effects can be increased when Methapyrilene is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04821</drugbank-id>
      <name>Nomifensine</name>
      <description>The risk or severity of adverse effects can be increased when Nomifensine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>The risk or severity of adverse effects can be increased when Urethane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04833</drugbank-id>
      <name>Methaqualone</name>
      <description>The risk or severity of adverse effects can be increased when Methaqualone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The risk or severity of adverse effects can be increased when Rapacuronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The risk or severity of adverse effects can be increased when Flunarizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04885</drugbank-id>
      <name>Cilansetron</name>
      <description>The risk or severity of adverse effects can be increased when Cilansetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>The risk or severity of adverse effects can be increased when Bifeprunox is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04903</drugbank-id>
      <name>Pagoclone</name>
      <description>The risk or severity of adverse effects can be increased when Pagoclone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04917</drugbank-id>
      <name>Renzapride</name>
      <description>The risk or severity of adverse effects can be increased when Renzapride is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05227</drugbank-id>
      <name>APD791</name>
      <description>The risk or severity of adverse effects can be increased when APD791 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The risk or severity of adverse effects can be increased when Brivaracetam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05542</drugbank-id>
      <name>Naronapride</name>
      <description>The risk or severity of adverse effects can be increased when Naronapride is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>The risk or severity of adverse effects can be increased when Naluzotan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05607</drugbank-id>
      <name>PRX-08066</name>
      <description>The risk or severity of adverse effects can be increased when PRX-08066 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>The risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The risk or severity of adverse effects can be increased when Gantacurium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>The risk or severity of adverse effects can be increased when Lumateperone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06109</drugbank-id>
      <name>YKP-1358</name>
      <description>The risk or severity of adverse effects can be increased when YKP-1358 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The risk or severity of adverse effects can be increased when Lacosamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06264</drugbank-id>
      <name>Tolperisone</name>
      <description>The risk or severity of adverse effects can be increased when Tolperisone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The risk or severity of adverse effects can be increased when Dotarizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The risk or severity of adverse effects can be increased when Remacemide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The risk or severity of adverse effects can be increased when Clomethiazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The risk or severity of adverse effects can be increased when Tramiprosate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06529</drugbank-id>
      <name>Ocinaplon</name>
      <description>The risk or severity of adverse effects can be increased when Ocinaplon is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The risk or severity of adverse effects can be increased when Gaboxadol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The risk or severity of adverse effects can be increased when Agomelatine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06660</drugbank-id>
      <name>Saredutant</name>
      <description>The risk or severity of adverse effects can be increased when Saredutant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>The risk or severity of adverse effects can be increased when Fospropofol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06753</drugbank-id>
      <name>Triclofos</name>
      <description>The risk or severity of adverse effects can be increased when Triclofos is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06797</drugbank-id>
      <name>Mebutamate</name>
      <description>The risk or severity of adverse effects can be increased when Mebutamate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The risk or severity of adverse effects can be increased when Wortmannin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The risk or severity of adverse effects can be increased when Sulthiame is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>The risk or severity of adverse effects can be increased when Cinitapride is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08839</drugbank-id>
      <name>Serotonin</name>
      <description>The risk or severity of adverse effects can be increased when Serotonin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08892</drugbank-id>
      <name>Arbaclofen Placarbil</name>
      <description>The risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Pomalidomide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The risk or severity of adverse effects can be increased when Ifenprodil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Hexamethonium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The risk or severity of adverse effects can be increased when Dimetacrine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>The risk or severity of adverse effects can be increased when Cyamemazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The risk or severity of adverse effects can be increased when Barbexaclone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The risk or severity of adverse effects can be increased when Beclamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09014</drugbank-id>
      <name>Captodiame</name>
      <description>The risk or severity of adverse effects can be increased when Captodiame is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>The risk or severity of adverse effects can be increased when Brotizolam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09021</drugbank-id>
      <name>Benzoctamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzoctamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The risk or severity of adverse effects can be increased when Tasimelteon is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09184</drugbank-id>
      <name>Edivoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Edivoxetine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09186</drugbank-id>
      <name>Nisoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Nisoxetine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09187</drugbank-id>
      <name>Lortalamine</name>
      <description>The risk or severity of adverse effects can be increased when Lortalamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09190</drugbank-id>
      <name>Talopram</name>
      <description>The risk or severity of adverse effects can be increased when Talopram is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>The risk or severity of adverse effects can be increased when Etoperidone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>The risk or severity of adverse effects can be increased when Blonanserin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09247</drugbank-id>
      <name>Iproclozide</name>
      <description>The risk or severity of adverse effects can be increased when Iproclozide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The risk or severity of adverse effects can be increased when Ramosetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>The risk or severity of adverse effects can be increased when Pyrantel is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Alfaxalone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The risk or severity of adverse effects can be increased when Doramectin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Medetomidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of adverse effects can be increased when Xylazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>The risk or severity of adverse effects can be increased when Propiopromazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of adverse effects can be increased when Romifidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The risk or severity of adverse effects can be increased when Tiletamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11552</drugbank-id>
      <name>Tricaine</name>
      <description>The risk or severity of adverse effects can be increased when Tricaine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of adverse effects can be increased when Detomidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11582</drugbank-id>
      <name>Thiocolchicoside</name>
      <description>The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11675</drugbank-id>
      <name>Mosapride</name>
      <description>The risk or severity of adverse effects can be increased when Mosapride is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11686</drugbank-id>
      <name>Iferanserin</name>
      <description>The risk or severity of adverse effects can be increased when Iferanserin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>The risk or severity of adverse effects can be increased when Tropisetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>The risk or severity of adverse effects can be increased when Tetrahydrocannabivarin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The risk or severity of adverse effects can be increased when Brexanolone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Etiracetam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11889</drugbank-id>
      <name>Lanicemine</name>
      <description>The risk or severity of adverse effects can be increased when Lanicemine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11957</drugbank-id>
      <name>Idalopirdine</name>
      <description>The risk or severity of adverse effects can be increased when Idalopirdine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12071</drugbank-id>
      <name>Vabicaserin</name>
      <description>The risk or severity of adverse effects can be increased when Vabicaserin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12105</drugbank-id>
      <name>Imagabalin</name>
      <description>The risk or severity of adverse effects can be increased when Imagabalin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12110</drugbank-id>
      <name>m-Chlorophenylpiperazine</name>
      <description>The risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12111</drugbank-id>
      <name>MK-212</name>
      <description>The risk or severity of adverse effects can be increased when MK-212 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The risk or severity of adverse effects can be increased when Vinpocetine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12177</drugbank-id>
      <name>Eplivanserin</name>
      <description>The risk or severity of adverse effects can be increased when Eplivanserin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12229</drugbank-id>
      <name>Cerlapirdine</name>
      <description>The risk or severity of adverse effects can be increased when Cerlapirdine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12308</drugbank-id>
      <name>Eltanolone</name>
      <description>The risk or severity of adverse effects can be increased when Eltanolone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The risk or severity of adverse effects can be increased when Carisbamate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>The risk or severity of adverse effects can be increased when Piclozotan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12395</drugbank-id>
      <name>Esreboxetine</name>
      <description>The risk or severity of adverse effects can be increased when Esreboxetine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12427</drugbank-id>
      <name>Orvepitant</name>
      <description>The risk or severity of adverse effects can be increased when Orvepitant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of adverse effects can be increased when Ketanserin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12537</drugbank-id>
      <name>Benzodiazepine</name>
      <description>The risk or severity of adverse effects can be increased when Benzodiazepine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12576</drugbank-id>
      <name>AZD-3043</name>
      <description>The risk or severity of adverse effects can be increased when AZD-3043 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12590</drugbank-id>
      <name>Indiplon</name>
      <description>The risk or severity of adverse effects can be increased when Indiplon is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The risk or severity of adverse effects can be increased when Urapidil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12725</drugbank-id>
      <name>TD-8954</name>
      <description>The risk or severity of adverse effects can be increased when TD-8954 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12883</drugbank-id>
      <name>Eltoprazine</name>
      <description>The risk or severity of adverse effects can be increased when Eltoprazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12951</drugbank-id>
      <name>Pivagabine</name>
      <description>The risk or severity of adverse effects can be increased when Pivagabine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>The risk or severity of adverse effects can be increased when Prothipendyl is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Neosaxitoxin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13099</drugbank-id>
      <name>Valnoctamide</name>
      <description>The risk or severity of adverse effects can be increased when Valnoctamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13196</drugbank-id>
      <name>Valerian</name>
      <description>The risk or severity of adverse effects can be increased when Valerian is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>The risk or severity of adverse effects can be increased when Butaperazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13219</drugbank-id>
      <name>Medifoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Medifoxamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13221</drugbank-id>
      <name>Apronalide</name>
      <description>The risk or severity of adverse effects can be increased when Apronalide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13234</drugbank-id>
      <name>Propanidid</name>
      <description>The risk or severity of adverse effects can be increased when Propanidid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The risk or severity of adverse effects can be increased when Quinupramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13253</drugbank-id>
      <name>Proxibarbal</name>
      <description>The risk or severity of adverse effects can be increased when Proxibarbal is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The risk or severity of adverse effects can be increased when Atracurium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13303</drugbank-id>
      <name>Febarbamate</name>
      <description>The risk or severity of adverse effects can be increased when Febarbamate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13324</drugbank-id>
      <name>Tetrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Tetrazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13331</drugbank-id>
      <name>Pyrithyldione</name>
      <description>The risk or severity of adverse effects can be increased when Pyrithyldione is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13354</drugbank-id>
      <name>Phenprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Phenprobamate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13357</drugbank-id>
      <name>Styramate</name>
      <description>The risk or severity of adverse effects can be increased when Styramate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The risk or severity of adverse effects can be increased when Pheneturide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13370</drugbank-id>
      <name>Bromisoval</name>
      <description>The risk or severity of adverse effects can be increased when Bromisoval is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13377</drugbank-id>
      <name>Vinbarbital</name>
      <description>The risk or severity of adverse effects can be increased when Vinbarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The risk or severity of adverse effects can be increased when Neocitrullamon is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13402</drugbank-id>
      <name>Acetylglycinamide chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>The risk or severity of adverse effects can be increased when Oxypertine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13414</drugbank-id>
      <name>Fenyramidol</name>
      <description>The risk or severity of adverse effects can be increased when Fenyramidol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>The risk or severity of adverse effects can be increased when Thiazinam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13457</drugbank-id>
      <name>Oxaflozane</name>
      <description>The risk or severity of adverse effects can be increased when Oxaflozane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The risk or severity of adverse effects can be increased when Emepronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>The risk or severity of adverse effects can be increased when Metergoline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13534</drugbank-id>
      <name>Gedocarnil</name>
      <description>The risk or severity of adverse effects can be increased when Gedocarnil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13541</drugbank-id>
      <name>Iprazochrome</name>
      <description>The risk or severity of adverse effects can be increased when Iprazochrome is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>The risk or severity of adverse effects can be increased when Moperone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>The risk or severity of adverse effects can be increased when Thiopropazate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13572</drugbank-id>
      <name>Emylcamate</name>
      <description>The risk or severity of adverse effects can be increased when Emylcamate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13577</drugbank-id>
      <name>Allobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Allobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The risk or severity of adverse effects can be increased when Gallamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13588</drugbank-id>
      <name>Naftidrofuryl</name>
      <description>The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Diethyl ether is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13623</drugbank-id>
      <name>Fabomotizole</name>
      <description>The risk or severity of adverse effects can be increased when Fabomotizole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13642</drugbank-id>
      <name>Pridinol</name>
      <description>The risk or severity of adverse effects can be increased when Pridinol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The risk or severity of adverse effects can be increased when Alcuronium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13662</drugbank-id>
      <name>Hexapropymate</name>
      <description>The risk or severity of adverse effects can be increased when Hexapropymate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>The risk or severity of adverse effects can be increased when Mosapramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13687</drugbank-id>
      <name>Niaprazine</name>
      <description>The risk or severity of adverse effects can be increased when Niaprazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13690</drugbank-id>
      <name>Vinyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Vinyl ether is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13733</drugbank-id>
      <name>Methylpentynol</name>
      <description>The risk or severity of adverse effects can be increased when Methylpentynol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13737</drugbank-id>
      <name>Cyclobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13745</drugbank-id>
      <name>Fazadinium bromide</name>
      <description>The risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13754</drugbank-id>
      <name>Mephenoxalone</name>
      <description>The risk or severity of adverse effects can be increased when Mephenoxalone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13770</drugbank-id>
      <name>Vinylbital</name>
      <description>The risk or severity of adverse effects can be increased when Vinylbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The risk or severity of adverse effects can be increased when Imipramine oxide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The risk or severity of adverse effects can be increased when Ethadione is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13805</drugbank-id>
      <name>Reposal</name>
      <description>The risk or severity of adverse effects can be increased when Reposal is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13817</drugbank-id>
      <name>Carbromal</name>
      <description>The risk or severity of adverse effects can be increased when Carbromal is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13837</drugbank-id>
      <name>Doxefazepam</name>
      <description>The risk or severity of adverse effects can be increased when Doxefazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>The risk or severity of adverse effects can be increased when Lormetazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13948</drugbank-id>
      <name>N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine</name>
      <description>The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13984</drugbank-id>
      <name>Cyclopropane</name>
      <description>The risk or severity of adverse effects can be increased when Cyclopropane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13993</drugbank-id>
      <name>MRK-409</name>
      <description>The risk or severity of adverse effects can be increased when MRK-409 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>The risk or severity of adverse effects can be increased when 5-methoxy-N,N-dimethyltryptamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The risk or severity of adverse effects can be increased when Cannabidivarin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14672</drugbank-id>
      <name>Oxazepam acetate</name>
      <description>The risk or severity of adverse effects can be increased when Oxazepam acetate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14715</drugbank-id>
      <name>Cinazepam</name>
      <description>The risk or severity of adverse effects can be increased when Cinazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14718</drugbank-id>
      <name>Pyrazolam</name>
      <description>The risk or severity of adverse effects can be increased when Pyrazolam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14719</drugbank-id>
      <name>Bentazepam</name>
      <description>The risk or severity of adverse effects can be increased when Bentazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>The risk or severity of adverse effects can be increased when Solriamfetol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Cetirizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The risk or severity of adverse effects can be increased when Trimethadione is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>The risk or severity of adverse effects can be increased when Triprolidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>The risk or severity of adverse effects can be increased when Moricizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Apomorphine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Isoflurane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of adverse effects can be increased when Propofol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Brompheniramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of adverse effects can be increased when Promethazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>The risk or severity of adverse effects can be increased when Levocabastine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The risk or severity of adverse effects can be increased when Cyclizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of adverse effects can be increased when Desflurane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Levetiracetam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Sevoflurane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>The risk or severity of adverse effects can be increased when Alimemazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The risk or severity of adverse effects can be increased when Ezogabine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Levocetirizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of adverse effects can be increased when Ziconotide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Rizatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15197</drugbank-id>
      <name>RSV-604</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with RSV-604.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with JNJ-26489112.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00150</drugbank-id>
      <name>Tryptophan</name>
      <description>The risk or severity of adverse effects can be increased when Tryptophan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The risk or severity of adverse effects can be increased when Reserpine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Temazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Reboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00371</drugbank-id>
      <name>Meprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Meprobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Remoxipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00546</drugbank-id>
      <name>Adinazolam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Adinazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Clorazepic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Halazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Progabide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Oxazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Gabapentin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Sibutramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01178</drugbank-id>
      <name>Chlormezanone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Chlormezanone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Estazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01445</drugbank-id>
      <name>Bufotenine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Bufotenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01463</drugbank-id>
      <name>Fencamfamin</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Fencamfamin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01488</drugbank-id>
      <name>Dimethyltryptamine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Tenamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Ethyl loflazepate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Bromazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01560</drugbank-id>
      <name>Cathinone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Cathinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Fludiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Prazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Nitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01954</drugbank-id>
      <name>Rolipram</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Rolipram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with 7-Nitroindazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02959</drugbank-id>
      <name>Oxitriptan</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Oxitriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03575</drugbank-id>
      <name>Phencyclidine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Phencyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04325</drugbank-id>
      <name>Phenethylamine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Phenethylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04599</drugbank-id>
      <name>Aniracetam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Aniracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Lysergic acid diethylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Deramciclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06579</drugbank-id>
      <name>Adipiplon</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Adipiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06582</drugbank-id>
      <name>Dextofisopam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Dextofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Esmirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Tofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08986</drugbank-id>
      <name>Etifoxine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Etifoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Vortioxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Etizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Viloxazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11555</drugbank-id>
      <name>Zolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Zolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11664</drugbank-id>
      <name>Psilocybin</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Psilocybin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12184</drugbank-id>
      <name>Gepirone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Gepirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12327</drugbank-id>
      <name>Salvinorin A</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Salvinorin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12833</drugbank-id>
      <name>Tandospirone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Tandospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13082</drugbank-id>
      <name>Nefiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Nefiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13335</drugbank-id>
      <name>Pinazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Pinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13352</drugbank-id>
      <name>Deanol</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Deanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Medazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Phenibut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13522</drugbank-id>
      <name>Mebicar</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Mebicar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13550</drugbank-id>
      <name>Bifemelane</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Bifemelane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13601</drugbank-id>
      <name>Oxiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Oxiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Loprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14028</drugbank-id>
      <name>Nordazepam</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Nordazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00574</drugbank-id>
      <name>Fenfluramine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Fenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Pentobarbital is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The risk or severity of adverse effects can be increased when Primidone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The risk or severity of adverse effects can be increased when St. John's Wort is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>The risk or severity of adverse effects can be increased when Mepyramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Donepezil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The serum concentration of Citalopram can be decreased when it is combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>The therapeutic efficacy of Salmon Calcitonin can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00066</drugbank-id>
      <name>Follitropin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Liothyronine can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The therapeutic efficacy of Carbimazole can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>The therapeutic efficacy of Tiratricol can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05084</drugbank-id>
      <name>Abaloparatide</name>
      <description>The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05829</drugbank-id>
      <name>Parathyroid hormone</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06285</drugbank-id>
      <name>Teriparatide</name>
      <description>The therapeutic efficacy of Teriparatide can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09421</drugbank-id>
      <name>Protirelin</name>
      <description>The therapeutic efficacy of Protirelin can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13742</drugbank-id>
      <name>Elcatonin</name>
      <description>The therapeutic efficacy of Elcatonin can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15263</drugbank-id>
      <name>Thyrotropin</name>
      <description>The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The therapeutic efficacy of Liotrix can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12629</drugbank-id>
      <name>3,5-diiodothyropropionic acid</name>
      <description>The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Licofelone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Polmacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Flurbiprofen axetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Metamizole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Propacetamol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Metixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Propantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>Citalopram may increase the central nervous system depressant (CNS depressant) activities of Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Goserelin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00556</drugbank-id>
      <name>Perflutren</name>
      <description>The risk or severity of QTc prolongation can be increased when Perflutren is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of QTc prolongation can be increased when Atropine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00640</drugbank-id>
      <name>Adenosine</name>
      <description>The risk or severity of QTc prolongation can be increased when Adenosine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00778</drugbank-id>
      <name>Roxithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Loperamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Granisetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01599</drugbank-id>
      <name>Probucol</name>
      <description>The risk or severity of QTc prolongation can be increased when Probucol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02638</drugbank-id>
      <name>Terlipressin</name>
      <description>The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04957</drugbank-id>
      <name>Azimilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Azimilide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05223</drugbank-id>
      <name>Pracinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06200</drugbank-id>
      <name>Tedisamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Tedisamil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06334</drugbank-id>
      <name>Tucidinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>The risk or severity of QTc prolongation can be increased when Telavancin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08799</drugbank-id>
      <name>Antazoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Antazoline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08903</drugbank-id>
      <name>Bedaquiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Fendiline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of QTc prolongation can be increased when Eperisone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Benidipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09555</drugbank-id>
      <name>Dexchlorpheniramine maleate</name>
      <description>The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11830</drugbank-id>
      <name>Mocetinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11841</drugbank-id>
      <name>Entinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Entinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12174</drugbank-id>
      <name>CUDC-101</name>
      <description>The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12286</drugbank-id>
      <name>Simendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Simendan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12376</drugbank-id>
      <name>Ricolinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12523</drugbank-id>
      <name>Mizolastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12565</drugbank-id>
      <name>Abexinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12877</drugbank-id>
      <name>Oxatomide</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of QTc prolongation can be increased when Otilonium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13546</drugbank-id>
      <name>Nizofenone</name>
      <description>The risk or severity of QTc prolongation can be increased when Nizofenone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13652</drugbank-id>
      <name>Bunaftine</name>
      <description>The risk or severity of QTc prolongation can be increased when Bunaftine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13653</drugbank-id>
      <name>Lorcainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Lorcainide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13679</drugbank-id>
      <name>Dexchlorpheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Dexverapamil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Indenolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Promazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of QTc prolongation can be increased when Melperone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The risk or severity of QTc prolongation can be increased when Sultopride is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00166</drugbank-id>
      <name>Lipoic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14025</drugbank-id>
      <name>Clinafloxacin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Clinafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Octreotide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00107</drugbank-id>
      <name>Oxytocin</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Esmolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Isradipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Buclizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Galantamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of QTc prolongation can be increased when Moexipril is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00719</drugbank-id>
      <name>Azatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Azatadine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Indapamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amantadine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00920</drugbank-id>
      <name>Ketotifen</name>
      <description>The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Famotidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Formoterol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The risk or severity of QTc prolongation can be increased when Bretylium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01228</drugbank-id>
      <name>Encainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Encainide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01426</drugbank-id>
      <name>Ajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01620</drugbank-id>
      <name>Pheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04695</drugbank-id>
      <name>Farnesyl thiopyrophosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05465</drugbank-id>
      <name>Tandutinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06217</drugbank-id>
      <name>Vernakalant</name>
      <description>The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06468</drugbank-id>
      <name>Cariporide</name>
      <description>The risk or severity of QTc prolongation can be increased when Cariporide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>The risk or severity of QTc prolongation can be increased when Degarelix is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Buserelin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Histrelin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07780</drugbank-id>
      <name>Farnesyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07841</drugbank-id>
      <name>Geranylgeranyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of QTc prolongation can be increased when Eribulin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08936</drugbank-id>
      <name>Chlorcyclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The risk or severity of QTc prolongation can be increased when Flumequine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Niguldipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11390</drugbank-id>
      <name>Coumaphos</name>
      <description>The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11397</drugbank-id>
      <name>Dichlorvos</name>
      <description>The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11408</drugbank-id>
      <name>Famphur</name>
      <description>The risk or severity of QTc prolongation can be increased when Famphur is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11412</drugbank-id>
      <name>Fenthion</name>
      <description>The risk or severity of QTc prolongation can be increased when Fenthion is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11448</drugbank-id>
      <name>Phosmet</name>
      <description>The risk or severity of QTc prolongation can be increased when Phosmet is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11591</drugbank-id>
      <name>Bilastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Bilastine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11614</drugbank-id>
      <name>Rupatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Talinolol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11891</drugbank-id>
      <name>CUDC-907</name>
      <description>The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12231</drugbank-id>
      <name>Temefos</name>
      <description>The risk or severity of QTc prolongation can be increased when Temefos is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12645</drugbank-id>
      <name>Givinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Givinostat is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13358</drugbank-id>
      <name>Cibenzoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13555</drugbank-id>
      <name>Prajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13651</drugbank-id>
      <name>Lorajmine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13744</drugbank-id>
      <name>Piromidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>The risk or severity of QTc prolongation can be increased when Inotersen is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Clemastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ibutilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Halofantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09083</drugbank-id>
      <name>Ivabradine</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ivabradine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Deutetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13074</drugbank-id>
      <name>Macimorelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Macimorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cocaine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The therapeutic efficacy of Citalopram can be increased when used in combination with Pregabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11637</drugbank-id>
      <name>Delamanid</name>
      <description>Citalopram may increase the QTc-prolonging activities of Delamanid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>The therapeutic efficacy of Citalopram can be decreased when used in combination with Patent Blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The therapeutic efficacy of Citalopram can be increased when used in combination with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Eptifibatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Tirofiban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Pentoxifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Sulfinpyrazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ridogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Resveratrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ibudilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Andrographolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Caplacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Icosapent ethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Trapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ifetroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Butylphthalide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Hydroxytyrosol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ramatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Picotamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Cloricromen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Linsidomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Buflomedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Relcovaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Semuloparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The metabolism of Aripiprazole lauroxil can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The metabolism of Hydrocodone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00426</drugbank-id>
      <name>Famciclovir</name>
      <description>The metabolism of Famciclovir can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The metabolism of Cephalexin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The metabolism of Norethisterone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01411</drugbank-id>
      <name>Pranlukast</name>
      <description>The metabolism of Pranlukast can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>The metabolism of Allylestrenol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>The metabolism of Roflumilast can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09274</drugbank-id>
      <name>Artesunate</name>
      <description>The metabolism of Artesunate can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11094</drugbank-id>
      <name>Vitamin D</name>
      <description>The metabolism of Vitamin D can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>The metabolism of Dihydroergocornine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12515</drugbank-id>
      <name>9-aminocamptothecin</name>
      <description>The metabolism of 9-aminocamptothecin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12952</drugbank-id>
      <name>Methylprednisone</name>
      <description>The metabolism of Methylprednisone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>The metabolism of Dihydroergocristine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>The metabolism of Dihydroergocryptine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The metabolism of Rosuvastatin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The metabolism of Drospirenone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15444</drugbank-id>
      <name>Elexacaftor</name>
      <description>The metabolism of Elexacaftor can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The metabolism of Triazolam can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The metabolism of Lurasidone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The metabolism of Tianeptine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The metabolism of Eletriptan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The metabolism of Indinavir can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>The metabolism of Methysergide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The metabolism of Dihydroergotamine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The metabolism of Nisoldipine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The metabolism of Buspirone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The metabolism of Ethosuximide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Cisapride can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The metabolism of Astemizole can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The metabolism of Simvastatin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The metabolism of Ergotamine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The metabolism of Conivaptan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Felodipine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The metabolism of Bromocriptine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The metabolism of Budesonide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The metabolism of Saquinavir can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Dasatinib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The metabolism of Darunavir can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The metabolism of Tolvaptan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06717</drugbank-id>
      <name>Fosaprepitant</name>
      <description>The metabolism of Fosaprepitant can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The metabolism of Rilpivirine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11742</drugbank-id>
      <name>Ebastine</name>
      <description>The metabolism of Ebastine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The metabolism of Siponimod can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Fosphenytoin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>The metabolism of Citalopram can be decreased when combined with Dofetilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The metabolism of Levothyroxine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The metabolism of Eplerenone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>The metabolism of Tadalafil can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The metabolism of Busulfan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The metabolism of Clindamycin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04835</drugbank-id>
      <name>Maraviroc</name>
      <description>The metabolism of Maraviroc can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06237</drugbank-id>
      <name>Avanafil</name>
      <description>The metabolism of Avanafil can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01201</drugbank-id>
      <name>Rifapentine</name>
      <description>The metabolism of Citalopram can be increased when combined with Rifapentine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The metabolism of Citalopram can be increased when combined with Rifabutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05077</drugbank-id>
      <name>SLV319</name>
      <description>The risk or severity of adverse effects can be increased when SLV319 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05372</drugbank-id>
      <name>CP-945598</name>
      <description>The risk or severity of adverse effects can be increased when CP-945598 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06155</drugbank-id>
      <name>Rimonabant</name>
      <description>The risk or severity of adverse effects can be increased when Rimonabant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06624</drugbank-id>
      <name>Taranabant</name>
      <description>The risk or severity of adverse effects can be increased when Taranabant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The risk or severity of adverse effects can be increased when Cannabidiol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11903</drugbank-id>
      <name>GW842166</name>
      <description>The risk or severity of adverse effects can be increased when GW842166 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12193</drugbank-id>
      <name>Ajulemic acid</name>
      <description>The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12649</drugbank-id>
      <name>Ibipinabant</name>
      <description>The risk or severity of adverse effects can be increased when Ibipinabant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13070</drugbank-id>
      <name>Surinabant</name>
      <description>The risk or severity of adverse effects can be increased when Surinabant is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The risk or severity of adverse effects can be increased when Nabiximols is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14043</drugbank-id>
      <name>Palmidrol</name>
      <description>The risk or severity of adverse effects can be increased when Palmidrol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14737</drugbank-id>
      <name>Cannabinol</name>
      <description>The risk or severity of adverse effects can be increased when Cannabinol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Pseudoephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Dexfenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Mephentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with 2,5-Dimethoxy-4-ethylamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Chlorphentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08167</drugbank-id>
      <name>Methylthioninium</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Methylthioninium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Iofetamine I-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10676</drugbank-id>
      <name>Nutmeg</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Nutmeg.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Ritobegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Mephedrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Methoxyphenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Gepefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13910</drugbank-id>
      <name>Valproate bismuth</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Valproate bismuth.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Citalopram can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Citalopram can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Citalopram can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Citalopram can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Citalopram can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Citalopram can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Citalopram can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Citalopram can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Citalopram can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Citalopram can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Citalopram can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Citalopram can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Citalopram can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Citalopram can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Citalopram can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>Citalopram may increase the QTc-prolonging activities of Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>Valproic acid may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>Gefitinib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>Sorafenib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Quinine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>Ritonavir may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>Mephenytoin may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>Carbamazepine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Nicardipine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>Losartan may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Warfarin may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>Amprenavir may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>Modafinil may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Methimazole may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>Oxcarbazepine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>Diazepam may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>Felbamate may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Telmisartan may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>Ketoconazole may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>Probenecid may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>Dimethyl sulfoxide may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>Fluvastatin may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>Miconazole may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Amiodarone may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>Bicalutamide may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Rabeprazole may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>Aminophenazone may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Topiroxostat may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Clevidipine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>Methsuximide may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>Etravirine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>Gestodene may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>Seproxetine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>Vismodegib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>Idelalisib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Lenvatinib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>Lobeglitazone may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>Rifamycin may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>Alpelisib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>Benzbromarone may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>Lynestrenol may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>Enasidenib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13941</drugbank-id>
      <name>Piperaquine</name>
      <description>Piperaquine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>Topiramate may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>Aprepitant may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>Avasimibe may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>Curcumin sulfate may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>Eslicarbazepine may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>Citalopram may increase the QTc-prolonging activities of Cenobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>The risk or severity of serotonin syndrome can be increased when Methylene blue is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Procaine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Phenelzine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Minaprine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Selegiline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Moclobemide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of serotonin syndrome can be increased when Isocarboxazid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Clorgiline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The risk or severity of serotonin syndrome can be increased when Iproniazid is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Nialamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Hydracarbazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>The risk or severity of serotonin syndrome can be increased when Pirlindole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Toloxatone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>The risk or severity of serotonin syndrome can be increased when Benmoxin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Mebanazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>The risk or severity of serotonin syndrome can be increased when Octamoxin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Pheniprazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Phenoxypropazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Pivhydrazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Safrazine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Caroxazone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Harmaline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Brofaromine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The risk or severity of adverse effects can be increased when Lithium cation is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Lithium citrate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Lithium carbonate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>The risk or severity of adverse effects can be increased when Lithium hydroxide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Sumatriptan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Citalopram can be decreased when combined with Triclabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Esketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The risk or severity of adverse effects can be increased when Carisoprodol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The risk or severity of CNS depression can be increased when Citalopram is combined with Eszopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of sedation can be increased when Clonidine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of QTc prolongation can be increased when Trazodone is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of bleeding can be increased when Celecoxib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Citalopram is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Citalopram may increase the QTc-prolonging activities of Lefamulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The risk or severity of CNS depression can be increased when Citalopram is combined with Cyclobenzaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of sedation can be increased when Metoclopramide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>Citalopram may increase the QTc-prolonging activities of Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14975</drugbank-id>
      <name>Voxelotor</name>
      <description>The serum concentration of Voxelotor can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The serum concentration of Tizanidine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Mitiglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Glymidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with AICA ribonucleotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Buformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Vildagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Voglibose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with NBI-6024.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with AMG-222.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Bisegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Gosogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Benfluorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Albiglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Lixisenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Ipragliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Dutogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Allicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Tofogliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with 2,4-thiazolidinedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Bempedoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Teneligliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Omarigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Carmegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Gemigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Anagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Evogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Sotagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Remogliflozin etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Guar gum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Semaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Taspoglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Englitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Tirzepatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Gastric inhibitory polypeptide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Acarbose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Miglitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Exenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Pramlintide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Liraglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Saxagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Netoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Rivoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Ciglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Balaglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The metabolism of Protriptyline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The metabolism of Amoxapine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The metabolism of Trimipramine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The metabolism of Opipramol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The metabolism of Carmustine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The metabolism of Triamterene can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00442</drugbank-id>
      <name>Entecavir</name>
      <description>The metabolism of Entecavir can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The metabolism of Guanabenz can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The metabolism of Pemetrexed can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>The metabolism of Thiabendazole can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The metabolism of Acyclovir can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The metabolism of Dacarbazine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The metabolism of Azathioprine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01056</drugbank-id>
      <name>Tocainide</name>
      <description>The metabolism of Tocainide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>The metabolism of Hesperetin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The metabolism of Leflunomide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The metabolism of Oxtriphylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The metabolism of Theobromine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The metabolism of Fenethylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The metabolism of 8-azaguanine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The metabolism of Xanthine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The metabolism of 9-Methylguanine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The metabolism of Peldesine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The metabolism of Hypoxanthine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The metabolism of 9-Deazaguanine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The metabolism of Pirfenidone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The metabolism of Propentofylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The metabolism of Bendamustine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The metabolism of Doxofylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The metabolism of Binimetinib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The metabolism of Lisofylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The metabolism of Lobucavir can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The metabolism of Cafedrine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The metabolism of Theodrenaline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The metabolism of Dihydralazine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The metabolism of Bamifylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The metabolism of Proxyphylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The metabolism of Acefylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The metabolism of Etamiphylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The metabolism of Pentifylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The metabolism of Bufylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The metabolism of Bromotheophylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The metabolism of 8-chlorotheophylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The metabolism of GTS-21 can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The metabolism of Caffeine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The metabolism of Ropivacaine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Flutamide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Zileuton can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The metabolism of Levobupivacaine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The metabolism of Estrone sulfate can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Capsaicin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The metabolism of 6-O-benzylguanine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09237</drugbank-id>
      <name>Levamlodipine</name>
      <description>The serum concentration of Levamlodipine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The therapeutic efficacy of Citalopram can be decreased when used in combination with Gilteritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Afatinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Bosutinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The serum concentration of Brentuximab vedotin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The serum concentration of Edoxaban can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ledipasvir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The serum concentration of Naloxegol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Pazopanib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Prucalopride can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Silodosin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The serum concentration of Topotecan can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Everolimus can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The serum concentration of Rifaximin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The excretion of Vincristine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The serum concentration of Betrixaban can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Sirolimus can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Quinidine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The serum concentration of Paclitaxel can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Citalopram may decrease the excretion rate of Digoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>Citalopram may decrease the excretion rate of Metildigoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>Citalopram may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The serum concentration of Midazolam can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Citalopram can be decreased when combined with Lorcaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The metabolism of Citalopram can be decreased when combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Citalopram can be decreased when combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The metabolism of Citalopram can be decreased when combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The metabolism of Citalopram can be decreased when combined with Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The metabolism of Citalopram can be decreased when combined with Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The metabolism of Nilotinib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>The metabolism of Lumefantrine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The metabolism of Venlafaxine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The metabolism of Clobazam can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Duloxetine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The metabolism of Chlorpromazine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Vilazodone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The metabolism of Ritanserin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The metabolism of Citalopram can be decreased when combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The metabolism of Metoprolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The metabolism of Tegaserod can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The metabolism of Citalopram can be decreased when combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The metabolism of Citalopram can be decreased when combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Citalopram can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The metabolism of Citalopram can be decreased when combined with Cholecalciferol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The metabolism of Citalopram can be decreased when combined with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06819</drugbank-id>
      <name>Phenylbutyric acid</name>
      <description>The metabolism of Citalopram can be decreased when combined with Phenylbutyric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The metabolism of Citalopram can be decreased when combined with Asunaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13174</drugbank-id>
      <name>Rhein</name>
      <description>The metabolism of Citalopram can be decreased when combined with Rhein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Citalopram can be decreased when combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The metabolism of Terfenadine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The metabolism of Darifenacin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The metabolism of Ticagrelor can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The metabolism of Thioridazine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Citalopram can be decreased when combined with Cinacalcet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The metabolism of Citalopram can be decreased when combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>The metabolism of Citalopram can be decreased when combined with Glycerol phenylbutyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The metabolism of Citalopram can be decreased when combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Estradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The serum concentration of Tenofovir disoproxil can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Acetaminophen can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The serum concentration of Cerivastatin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The serum concentration of Gemcitabine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Betamethasone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The serum concentration of Teniposide can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Prazosin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The serum concentration of Raloxifene can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The serum concentration of Vinblastine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Ivermectin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Prednisone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Daunorubicin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>The serum concentration of Nitrofurantoin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Hydrocortisone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Tetracycline can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Etoposide can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Prednisolone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Ranitidine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Methylprednisolone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Dactinomycin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The serum concentration of Ezetimibe can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Nadolol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Mitoxantrone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Docetaxel can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The serum concentration of Taurocholic acid can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Estriol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Aldosterone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Debrisoquine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Trastuzumab emtansine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Simeprevir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The serum concentration of Dapagliflozin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Cabazitaxel can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Fidaxomicin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The serum concentration of Regorafenib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Ponatinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Fluticasone furoate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The serum concentration of Canagliflozin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The serum concentration of Palbociclib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The serum concentration of Dasabuvir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The serum concentration of Paritaprevir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The serum concentration of Tenofovir alafenamide can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Osimertinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Venetoclax can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Velpatasvir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Tezacaftor can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Valspodar can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The serum concentration of Elagolix can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Abemaciclib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Voxilaprevir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The serum concentration of Letermovir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Lusutrombopag can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The serum concentration of Fluticasone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The serum concentration of Pibrentasvir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The serum concentration of Glecaprevir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The serum concentration of Estradiol acetate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The serum concentration of Estradiol benzoate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The serum concentration of Estradiol cypionate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The serum concentration of Estradiol dienanthate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The serum concentration of Estradiol valerate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>The serum concentration of Valinomycin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The serum concentration of Tenofovir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00360</drugbank-id>
      <name>Sapropterin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Sapropterin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Albendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00520</drugbank-id>
      <name>Caspofungin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Caspofungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Testosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Clofazimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01103</drugbank-id>
      <name>Quinacrine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Quinacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01117</drugbank-id>
      <name>Atovaquone</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Atovaquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Ceftriaxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Cefoperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02010</drugbank-id>
      <name>Staurosporine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Staurosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02587</drugbank-id>
      <name>Colforsin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Colforsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Quercetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04540</drugbank-id>
      <name>Cholesterol</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Cholesterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04851</drugbank-id>
      <name>Biricodar</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Biricodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04877</drugbank-id>
      <name>Voacamine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Voacamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Elacridar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04960</drugbank-id>
      <name>Tipifarnib</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Tipifarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06191</drugbank-id>
      <name>Zosuquidar</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Zosuquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06240</drugbank-id>
      <name>Tariquidar</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Tariquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>Annamycin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Annamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06448</drugbank-id>
      <name>Lonafarnib</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Lonafarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06733</drugbank-id>
      <name>Bafilomycin A1</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Bafilomycin A1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06734</drugbank-id>
      <name>Bafilomycin B1</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Bafilomycin B1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Ivacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Daclatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Glycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11387</drugbank-id>
      <name>Chloroform</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Chloroform.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11430</drugbank-id>
      <name>Monensin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Monensin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11544</drugbank-id>
      <name>Salinomycin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Salinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Sarecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12582</drugbank-id>
      <name>Piperine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Piperine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12799</drugbank-id>
      <name>Laniquidar</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Laniquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Testosterone undecanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14056</drugbank-id>
      <name>Nigericin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Nigericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14061</drugbank-id>
      <name>Hycanthone</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Hycanthone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14062</drugbank-id>
      <name>Concanamycin A</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Concanamycin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14067</drugbank-id>
      <name>Dofequidar</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Dofequidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14069</drugbank-id>
      <name>ONT-093</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with ONT-093.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14070</drugbank-id>
      <name>HM-30181</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with HM-30181.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14071</drugbank-id>
      <name>Desmethylsertraline</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Desmethylsertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14072</drugbank-id>
      <name>Reversin 121</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Reversin 121.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Fedratinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The serum concentration of Anastrozole can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The serum concentration of Itraconazole can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Naloxone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Telaprevir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Trastuzumab deruxtecan can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>The serum concentration of Darolutamide can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Citalopram can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The metabolism of Cyclophosphamide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Proguanil can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Seratrodast can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The metabolism of Dexrabeprazole can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The metabolism of Thiopental can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Medical Cannabis can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>The metabolism of Cevimeline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The metabolism of Bupivacaine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The metabolism of Atenolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Mexiletine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>The metabolism of Piperazine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>The metabolism of Nicergoline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The metabolism of Tamsulosin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The metabolism of Nateglinide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The metabolism of Phenformin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The metabolism of Idarubicin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The metabolism of Bevantolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The metabolism of Practolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01429</drugbank-id>
      <name>Aprindine</name>
      <description>The metabolism of Aprindine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The metabolism of Nebivolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The metabolism of Trabectedin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The metabolism of Alogliptin can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06608</drugbank-id>
      <name>Tafenoquine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The metabolism of Bufuralol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06727</drugbank-id>
      <name>Sparteine</name>
      <description>The metabolism of Sparteine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06735</drugbank-id>
      <name>Enclomiphene</name>
      <description>The metabolism of Enclomiphene can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The metabolism of Bopindolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The metabolism of Befunolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>The metabolism of Lorpiprazole can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The metabolism of Arotinolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The metabolism of Levobetaxolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11718</drugbank-id>
      <name>Encorafenib</name>
      <description>The metabolism of Encorafenib can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>The metabolism of Valbenazine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The metabolism of Landiolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The metabolism of Bucindolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The metabolism of Ipecac can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The metabolism of Esatenolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The metabolism of Cloranolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The metabolism of Mepindolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The metabolism of Epanolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The metabolism of Tertatolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Citalopram can be decreased when combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The metabolism of Citalopram can be decreased when combined with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00792</drugbank-id>
      <name>Tripelennamine</name>
      <description>The metabolism of Citalopram can be decreased when combined with Tripelennamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The metabolism of Citalopram can be decreased when combined with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The metabolism of Citalopram can be decreased when combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11994</drugbank-id>
      <name>Diacerein</name>
      <description>The metabolism of Citalopram can be decreased when combined with Diacerein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06506</drugbank-id>
      <name>Repinotan</name>
      <description>The metabolism of Repinotan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09173</drugbank-id>
      <name>Butyrfentanyl</name>
      <description>The metabolism of Butyrfentanyl can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The metabolism of Ciclesonide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The metabolism of Lercanidipine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01096</drugbank-id>
      <name>Oxamniquine</name>
      <description>The metabolism of Citalopram can be decreased when combined with Oxamniquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Bicifadine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01562</drugbank-id>
      <name>1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine</name>
      <description>The metabolism of Citalopram can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The metabolism of Citalopram can be decreased when combined with Levosalbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Nevirapine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The metabolism of Citalopram can be decreased when combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The metabolism of Citalopram can be decreased when combined with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>The metabolism of Citalopram can be decreased when combined with Oxymetholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Citalopram can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The metabolism of Citalopram can be decreased when combined with Niacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The metabolism of Citalopram can be decreased when combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The metabolism of Citalopram can be decreased when combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The metabolism of Citalopram can be decreased when combined with Ospemifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The metabolism of Sotalol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The metabolism of Procainamide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Flecainide can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00126</drugbank-id>
      <name>Ascorbic acid</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Ascorbic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Pravastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated estrogens can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The serum concentration of Chlorambucil can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The serum concentration of Mitomycin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Vinorelbine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Tacrine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The serum concentration of Lenalidomide can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The serum concentration of Cisplatin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Alitretinoin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Methotrexate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Nizatidine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The serum concentration of Bisoprolol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The serum concentration of Mycophenolate mofetil can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Lamivudine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Mannitol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The serum concentration of Irinotecan can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Clomifene can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The serum concentration of Cytarabine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The serum concentration of Melphalan can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The serum concentration of Sitagliptin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Neostigmine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The serum concentration of Testosterone propionate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>The serum concentration of Stanolone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Sphingosine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Rhodamine 6G can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The serum concentration of Camptothecin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The serum concentration of Belinostat can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Cobimetinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Ambrisentan can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Axitinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The serum concentration of Odanacatib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The serum concentration of Pitavastatin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The serum concentration of Dolutegravir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The serum concentration of Olaparib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The serum concentration of Nintedanib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The serum concentration of Ombitasvir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The serum concentration of Selexipag can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>The serum concentration of Moxidectin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The serum concentration of Talazoparib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Baricitinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The serum concentration of Ertugliflozin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The serum concentration of Revefenacin can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The serum concentration of Duvelisib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The serum concentration of Copanlisib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>The serum concentration of Stanolone acetate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The serum concentration of Larotrectinib can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The risk or severity of QTc prolongation can be increased when Sildenafil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Pantoprazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Omeprazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Clozapine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Nilutamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Esomeprazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Tipranavir is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The risk or severity of QTc prolongation can be increased when Memantine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of QTc prolongation can be increased when Etoricoxib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04911</drugbank-id>
      <name>Oritavancin</name>
      <description>The risk or severity of QTc prolongation can be increased when Oritavancin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Dexlansoprazole is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Dovitinib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The risk or severity of QTc prolongation can be increased when Sitaxentan is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The risk or severity of QTc prolongation can be increased when Midostaurin is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Manidipine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11638</drugbank-id>
      <name>Artenimol</name>
      <description>The risk or severity of QTc prolongation can be increased when Artenimol is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The risk or severity of QTc prolongation can be increased when Rucaparib is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The risk or severity of QTc prolongation can be increased when Fenofibrate is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The metabolism of Timolol can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Givosiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15328</drugbank-id>
      <name>Ubrogepant</name>
      <description>The serum concentration of Ubrogepant can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The serum concentration of Cilostazol can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The metabolism of Atomoxetine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Pitolisant can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of QTc prolongation can be increased when Epirubicin is combined with Citalopram.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.58</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.88e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>recital</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>324.3919</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>324.163791509</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H21FN2O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>WSEQXVZVJXJVFP-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>36.26</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>94.02</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>35.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Sparingly soluble </value>
      <source>https://www.chemicalbook.com/ChemicalProductProperty_US_CB2736240.aspx</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>182-188</value>
      <source>https://www.chemicalbook.com/ChemicalProductProperty_US_CB2736240.aspx</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>347-358</value>
      <source>http://datasheets.scbt.com/sc-201123.pdf</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.76</value>
      <source>http://www.t3db.ca/toxins/T3D2715</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.7</value>
      <source>http://www.t3db.ca/toxins/T3D2715</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>9.78</value>
      <source>http://www.t3db.ca/toxins/T3D2715</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11847</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>77397</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>2771</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508746</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07572</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D07704</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>2669</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>25870</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449015</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000118</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Citalopram</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL549</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/citalo.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/citalopram.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000424</smpdb-id>
      <name>Citalopram Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00157</drugbank-id>
          <name>NADH</name>
        </drug>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00215</drugbank-id>
          <name>Citalopram</name>
        </drug>
        <drug>
          <drugbank-id>DB00368</drugbank-id>
          <name>Norepinephrine</name>
        </drug>
        <drug>
          <drugbank-id>DB00988</drugbank-id>
          <name>Dopamine</name>
        </drug>
        <drug>
          <drugbank-id>DB01345</drugbank-id>
          <name>Potassium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
        <drug>
          <drugbank-id>DB01828</drugbank-id>
          <name>Methylamine</name>
        </drug>
        <drug>
          <drugbank-id>DB02577</drugbank-id>
          <name>Mesoheme</name>
        </drug>
        <drug>
          <drugbank-id>DB03147</drugbank-id>
          <name>Flavin adenine dinucleotide</name>
        </drug>
        <drug>
          <drugbank-id>DB03843</drugbank-id>
          <name>Formaldehyde</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P31645</uniprot-id>
        <uniprot-id>P21397</uniprot-id>
        <uniprot-id>P27338</uniprot-id>
        <uniprot-id>Q06278</uniprot-id>
        <uniprot-id>P10635</uniprot-id>
        <uniprot-id>P24462</uniprot-id>
        <uniprot-id>P33261</uniprot-id>
        <uniprot-id>P17787</uniprot-id>
        <uniprot-id>P43681</uniprot-id>
        <uniprot-id>O00555</uniprot-id>
        <uniprot-id>Q02641</uniprot-id>
        <uniprot-id>Q9NY47</uniprot-id>
        <uniprot-id>Q9Y5Y9</uniprot-id>
        <uniprot-id>Q07699</uniprot-id>
        <uniprot-id>Q9NZV8</uniprot-id>
        <uniprot-id>Q9NS61</uniprot-id>
        <uniprot-id>P05023</uniprot-id>
        <uniprot-id>P50993</uniprot-id>
        <uniprot-id>P13637</uniprot-id>
        <uniprot-id>Q13733</uniprot-id>
        <uniprot-id>P05026</uniprot-id>
        <uniprot-id>P14415</uniprot-id>
        <uniprot-id>P54709</uniprot-id>
        <uniprot-id>B7ZKV8</uniprot-id>
        <uniprot-id>P54710</uniprot-id>
        <uniprot-id>P01189</uniprot-id>
        <uniprot-id>P01203</uniprot-id>
        <uniprot-id>P16519</uniprot-id>
        <uniprot-id>Q05586</uniprot-id>
        <uniprot-id>Q12879</uniprot-id>
        <uniprot-id>Q8TCU5</uniprot-id>
        <uniprot-id>P35348</uniprot-id>
        <uniprot-id>P08908</uniprot-id>
        <uniprot-id>P23975</uniprot-id>
        <uniprot-id>Q01959</uniprot-id>
        <uniprot-id>P21728</uniprot-id>
        <uniprot-id>P35372</uniprot-id>
      </enzymes>
    </pathway>
    <pathway>
      <smpdb-id>SMP0000627</smpdb-id>
      <name>Citalopram Metabolism Pathway</name>
      <category>drug_metabolism</category>
      <drugs>
        <drug>
          <drugbank-id>DB00157</drugbank-id>
          <name>NADH</name>
        </drug>
        <drug>
          <drugbank-id>DB00215</drugbank-id>
          <name>Citalopram</name>
        </drug>
        <drug>
          <drugbank-id>DB01828</drugbank-id>
          <name>Methylamine</name>
        </drug>
        <drug>
          <drugbank-id>DB02577</drugbank-id>
          <name>Mesoheme</name>
        </drug>
        <drug>
          <drugbank-id>DB03147</drugbank-id>
          <name>Flavin adenine dinucleotide</name>
        </drug>
        <drug>
          <drugbank-id>DB03843</drugbank-id>
          <name>Formaldehyde</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P31645</uniprot-id>
        <uniprot-id>P21397</uniprot-id>
        <uniprot-id>P27338</uniprot-id>
        <uniprot-id>Q06278</uniprot-id>
        <uniprot-id>P10635</uniprot-id>
        <uniprot-id>P24462</uniprot-id>
        <uniprot-id>P33261</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00215</drugbank-id>
        <name>Citalopram</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02225</drugbank-id>
        <name>Citalopram-N-oxide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002196</drugbank-id>
          <name>Amine oxidase [flavin-containing] B</name>
          <uniprot-id>P27338</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002198</drugbank-id>
          <name>Amine oxidase [flavin-containing] A</name>
          <uniprot-id>P21397</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003539</drugbank-id>
          <name>Aldehyde oxidase</name>
          <uniprot-id>Q06278</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00215</drugbank-id>
        <name>Citalopram</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02226</drugbank-id>
        <name>inactive deaminated propionic acid derivative</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002196</drugbank-id>
          <name>Amine oxidase [flavin-containing] B</name>
          <uniprot-id>P27338</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002198</drugbank-id>
          <name>Amine oxidase [flavin-containing] A</name>
          <uniprot-id>P21397</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003539</drugbank-id>
          <name>Aldehyde oxidase</name>
          <uniprot-id>Q06278</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00215</drugbank-id>
        <name>Citalopram</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02223</drugbank-id>
        <name>didemethylcitalopram</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002363</drugbank-id>
          <name>Cytochrome P450 2D6</name>
          <uniprot-id>P10635</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00215</drugbank-id>
        <name>Citalopram</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02224</drugbank-id>
        <name>demethylcitalopram</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0003536</drugbank-id>
          <name>Cytochrome P450 2C19</name>
          <uniprot-id>P33261</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00215</drugbank-id>
        <name>Citalopram</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00196</drugbank-id>
        <name>N-Desmethylcitalopram</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002363</drugbank-id>
          <name>Cytochrome P450 2D6</name>
          <uniprot-id>P10635</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003536</drugbank-id>
          <name>Cytochrome P450 2C19</name>
          <uniprot-id>P33261</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects>
    <effect>
      <protein-name>Multidrug resistance protein 1</protein-name>
      <gene-symbol>ABCB1</gene-symbol>
      <uniprot-id>P08183</uniprot-id>
      <rs-id>rs2032583</rs-id>
      <allele/>
      <defining-change>C Allele</defining-change>
      <description>Patients with this genotype have an increased likelihood of remission when using citalopram to treat major depressive disorder</description>
      <pubmed-id>17913323</pubmed-id>
    </effect>
    <effect>
      <protein-name>5-hydroxytryptamine receptor 2A</protein-name>
      <gene-symbol>HTR2A</gene-symbol>
      <uniprot-id>P28223</uniprot-id>
      <rs-id>rs7997012</rs-id>
      <allele/>
      <defining-change>A Allele</defining-change>
      <description>Patients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorder</description>
      <pubmed-id>16642436</pubmed-id>
    </effect>
    <effect>
      <protein-name>Glutamate receptor ionotropic, kainate 4</protein-name>
      <gene-symbol>GRIK4</gene-symbol>
      <uniprot-id>Q16099</uniprot-id>
      <rs-id>rs1954787</rs-id>
      <allele/>
      <defining-change>C Allele</defining-change>
      <description>Patients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorder</description>
      <pubmed-id>17671280</pubmed-id>
    </effect>
  </snp-effects>
  <snp-adverse-drug-reactions>
    <reaction>
      <protein-name>Glutamate receptor ionotropic, kainate 2</protein-name>
      <gene-symbol>GRIK2</gene-symbol>
      <uniprot-id>Q13002</uniprot-id>
      <rs-id>rs2518224</rs-id>
      <allele/>
      <adverse-reaction>C Allele, homozygote</adverse-reaction>
      <description>Patients with this genotype have increased frequency of suicidal ideation with citalopram</description>
      <pubmed-id>17898344</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Glutamate receptor 3</protein-name>
      <gene-symbol>GRIA3</gene-symbol>
      <uniprot-id>P42263</uniprot-id>
      <rs-id>rs4825476</rs-id>
      <allele/>
      <adverse-reaction>G allele</adverse-reaction>
      <description>Patients with this genotype have increased frequency of suicidal ideation with citalopram</description>
      <pubmed-id>17898344</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Cyclic AMP-responsive element-binding protein 1</protein-name>
      <gene-symbol>CREB1</gene-symbol>
      <uniprot-id>P16220</uniprot-id>
      <rs-id>rs4675690</rs-id>
      <allele/>
      <adverse-reaction>T allele, homozygous</adverse-reaction>
      <description>Male patients with this genotype have an increased risk of (condition: suicide) with (drug: citalopram).</description>
      <pubmed-id>17548750</pubmed-id>
    </reaction>
  </snp-adverse-drug-reactions>
  <targets>
    <target position="1">
      <id>BE0000749</id>
      <name>Sodium-dependent serotonin transporter</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37688</ref-id>
            <pubmed-id>21546862</pubmed-id>
            <citation>Sangkuhl K, Klein TE, Altman RB: PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72. doi: 10.1097/FPC.0b013e328346063f.</citation>
          </article>
          <article>
            <ref-id>A174415</ref-id>
            <pubmed-id>27049939</pubmed-id>
            <citation>Coleman JA, Green EM, Gouaux E: X-ray structures and mechanism of the human serotonin transporter. Nature. 2016 Apr 21;532(7599):334-9. doi: 10.1038/nature17629. Epub 2016 Apr 6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P31645" source="Swiss-Prot">
        <name>Sodium-dependent serotonin transporter</name>
        <general-function>Serotonin:sodium symporter activity</general-function>
        <specific-function>Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.</specific-function>
        <gene-name>SLC6A4</gene-name>
        <locus>17q11.1-q12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>88-108
116-135
160-180
253-271
280-297
333-350
362-383
417-436
464-482
498-518
539-558
577-595</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.17</theoretical-pi>
        <molecular-weight>70324.165</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11050</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC6A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X70697</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>36433</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31645</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SC6A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5HT transporter</synonym>
          <synonym>5HTT</synonym>
          <synonym>HTT</synonym>
          <synonym>SERT</synonym>
          <synonym>Solute carrier family 6 member 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001494|Sodium-dependent serotonin transporter
METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTR
HSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLP
YTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIM
AWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIH
RSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGA
TLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQD
ALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPAS
TFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVT
LTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRIC
WVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIIT
PGTFKERIIKSITPETPTEIPCGDIRLNAV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021275|Sodium-dependent serotonin transporter (SLC6A4)
ATGGAGACGACGCCCTTGAATTCTCAGAAGCAGCTATCAGCGTGTGAAGATGGAGAAGAT
TGTCAGGAAAACGGAGTTCTACAGAAGGTTGTTCCCACCCCAGGGGACAAAGTGGAGTCC
GGGCAAATATCCAATGGGTACTCAGCAGTTCCAAGTCCTGGTGCGGGAGATGACACACGG
CACTCTATCCCAGCGACCACCACCACCCTAGTGGCTGAGCTTCATCAAGGGGAACGGGAG
ACCTGGGGCAAGAAGGTGGATTTCCTTCTCTCAGTGATTGGCTATGCTGTGGACCTGGGC
AATGTCTGGCGCTTCCCCTACATATGTTACCAGAATGGAGGGGGGGCATTCCTCCTCCCC
TACACCATCATGGCCATTTTTGGGGGAATCCCGCTCTTTTACATGGAGCTCGCACTGGGA
CAGTACCACCGAAATGGATGCATTTCAATATGGAGGAAAATCTGCCCGATTTTCAAAGGG
ATTGGTTATGCCATCTGCATCATTGCCTTTTACATTGCTTCCTACTACAACACCATCATG
GCCTGGGCGCTATACTACCTCATCTCCTCCTTCACGGACCAGCTGCCCTGGACCAGCTGC
AAGAACTCCTGGAACACTGGCAACTGCACCAATTACTTCTCCGAGGACAACATCACCTGG
ACCCTCCATTCCACGTCCCCTGCTGAAGAATTTTACACGCGCCACGTCCTGCAGATCCAC
CGGTCTAAGGGGCTCCAGGACCTGGGGGGCATCAGCTGGCAGCTGGCCCTCTGCATCATG
CTGATCTTCACTGTTATCTACTTCAGCATCTGGAAAGGCGTCAAGACCTCTGGCAAGGTG
GTGTGGGTGACAGCCACCTTCCCTTATATCATCCTTTCTGTCCTGCTGGTGAGGGGTGCC
ACCCTCCCTGGAGCCTGGAGGGGTGTTCTCTTCTACTTGAAACCCAATTGGCAGAAACTC
CTGGAGACAGGGGTGTGGATAGATGCAGCCGCTCAGATCTTCTTCTCTCTTGGTCCGGGC
TTTGGGGTCCTGCTGGCTTTTGCTAGCTACAACAAGTTCAACAACAACTGCTACCAAGAT
GCCCTGGTGACCAGCGTGGTGAACTGCATGACGAGCTTCGTTTCGGGATTTGTCATCTTC
ACAGTGCTCGGTTACATGGCTGAGATGAGGAATGAAGATGTGTCTGAGGTGGCCAAAGAC
GCAGGTCCCAGCCTCCTCTTCATCACGTATGCAGAAGCGATAGCCAACATGCCAGCGTCC
ACTTTCTTTGCCATCATCTTCTTTCTGATGTTAATCACGCTGGGCTTGGACAGCACGTTT
GCAGGCTTGGAGGGGGTGATCACGGCTGTGCTGGATGAGTTCCCACACGTCTGGGCCAAG
CGCCGGGAGCGGTTCGTGCTCGCCGTGGTCATCACCTGCTTCTTTGGATCCCTGGTCACC
CTGACTTTTGGAGGGGCCTACGTGGTGAAGCTGCTGGAGGAGTATGCCACGGGGCCCGCA
GTGCTCACTGTCGCGCTGATCGAAGCAGTCGCTGTGTCTTGGTTCTATGGCATCACTCAG
TTCTGCAGGGACGTGAAGGAAATGCTCGGCTTCAGCCCGGGGTGGTTCTGGAGGATCTGC
TGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTCATCATTTGCAGTTTTCTGATGAGCCCG
CCACAACTACGACTTTTCCAATATAATTATCCTTACTGGAGTATCATCTTGGGTTACTGC
ATAGGAACCTCATCTTTCATTTGCATCCCCACATATATAGCTTATCGGTTGATCATCACT
CCAGGGACATTTAAAGAGCGTATTATTAAAAGTATTACCCCAGAAACACCAACAGAAATT
CCTTGTGGGGACATCCGCTTGAATGCTGTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00209</identifier>
            <name>SNF</name>
          </pfam>
          <pfam>
            <identifier>PF03491</identifier>
            <name>5HT_transport_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endomembrane system</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>actin filament binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cocaine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monoamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Rab GTPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cGMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cerebellar granule cell precursor proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin uptake</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sperm ejaculation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thalamus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000442</id>
      <name>Histamine H1 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4337</ref-id>
            <pubmed-id>17916059</pubmed-id>
            <citation>Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F3286</ref-id>
            <title>Citalopram MedSafe NZ Data Sheet</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/286/original/ArrowCitalopramtab.pdf?1549058639</url>
          </attachment>
        </attachments>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P35367" source="Swiss-Prot">
        <name>Histamine H1 receptor</name>
        <general-function>Histamine receptor activity</general-function>
        <specific-function>In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.</specific-function>
        <gene-name>HRH1</gene-name>
        <locus>3p25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>30-52
63-83
102-123
144-164
190-210
417-438
451-470</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.58</theoretical-pi>
        <molecular-weight>55783.61</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5182</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HRH1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z34897</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>510296</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>262</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>262</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35367</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HRH1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>H1R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016092|Histamine H1 receptor
MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT
VGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFI
LCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKC
ETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLR
PENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKL
YCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSR
TDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFI
MAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFK
RILHIRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016093|Histamine H1 receptor (HRH1)
ATGAGCCTCCCCAATTCCTCCTGCCTCTTAGAAGACAAGATGTGTGAGGGCAACAAGACC
ACTATGGCCAGCCCCCAGCTGATGCCCCTGGTGGTGGTCCTGAGCACTATCTGCTTGGTC
ACAGTAGGGCTCAACCTGCTGGTGCTGTATGCCGTACGGAGTGAGCGGAAGCTCCACACT
GTGGGGAACCTGTACATCGTCAGCCTCTCGGTGGCGGACTTGATCGTGGGTGCCGTCGTC
ATGCCTATGAACATCCTCTACCTGCTCATGTCCAAGTGGTCACTGGGCCGTCCTCTCTGC
CTCTTTTGGCTTTCCATGGACTATGTGGCCAGCACAGCGTCCATTTTCAGTGTCTTCATC
CTGTGCATTGATCGCTACCGCTCTGTCCAGCAGCCCCTCAGGTACCTTAAGTATCGTACC
AAGACCCGAGCCTCGGCCACCATTCTGGGGGCCTGGTTTCTCTCTTTTCTGTGGGTTATT
CCCATTCTAGGCTGGAATCACTTCATGCAGCAGACCTCGGTGCGCCGAGAGGACAAGTGT
GAGACAGACTTCTATGATGTCACCTGGTTCAAGGTCATGACTGCCATCATCAACTTCTAC
CTGCCCACCTTGCTCATGCTCTGGTTCTATGCCAAGATCTACAAGGCCGTACGACAACAC
TGCCAGCACCGGGAGCTCATCAATAGGTCCCTCCCTTCCTTCTCAGAAATTAAGCTGAGG
CCAGAGAACCCCAAGGGGGATGCCAAGAAACCAGGGAAGGAGTCTCCCTGGGAGGTTCTG
AAAAGGAAGCCAAAAGATGCTGGTGGTGGATCTGTCTTGAAGTCACCATCCCAAACCCCC
AAGGAGATGAAATCCCCAGTTGTCTTCAGCCAAGAGGATGATAGAGAAGTAGACAAACTC
TACTGCTTTCCACTTGATATTGTGCACATGCAGGCTGCGGCAGAGGGGAGTAGCAGGGAC
TATGTAGCCGTCAACCGGAGCCATGGCCAGCTCAAGACAGATGAGCAGGGCCTGAACACA
CATGGGGCCAGCGAGATATCAGAGGATCAGATGTTAGGTGATAGCCAATCCTTCTCTCGA
ACGGACTCAGATACCACCACAGAGACAGCACCAGGCAAAGGCAAATTGAGGAGTGGGTCT
AACACAGGCCTGGATTACATCAAGTTTACTTGGAAGAGGCTCCGCTCGCATTCAAGACAG
TATGTATCTGGGTTGCACATGAACCGCGAAAGGAAGGCCGCCAAACAGTTGGGTTTTATC
ATGGCAGCCTTCATCCTCTGCTGGATCCCTTATTTCATCTTCTTCATGGTCATTGCCTTC
TGCAAGAACTGTTGCAATGAACATTTGCACATGTTCACCATCTGGCTGGGCTACATCAAC
TCCACACTGAACCCCCTCATCTACCCCTTGTGCAATGAGAACTTCAAGAAGACATTCAAG
AGAATTCTGCATATTCGCTCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eosinophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inositol phosphate-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>modulation of synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inositol trisphosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="0">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14733</ref-id>
            <pubmed-id>11532381</pubmed-id>
            <citation>Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83.</citation>
          </article>
          <article>
            <ref-id>A14723</ref-id>
            <pubmed-id>10774624</pubmed-id>
            <citation>Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.</citation>
          </article>
          <article>
            <ref-id>A415</ref-id>
            <pubmed-id>19515014</pubmed-id>
            <citation>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</citation>
          </article>
          <article>
            <ref-id>A14734</ref-id>
            <pubmed-id>9890159</pubmed-id>
            <citation>Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53.</citation>
          </article>
          <article>
            <ref-id>A37688</ref-id>
            <pubmed-id>21546862</pubmed-id>
            <citation>Sangkuhl K, Klein TE, Altman RB: PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72. doi: 10.1097/FPC.0b013e328346063f.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0003536</id>
      <name>Cytochrome P450 2C19</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14733</ref-id>
            <pubmed-id>11532381</pubmed-id>
            <citation>Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83.</citation>
          </article>
          <article>
            <ref-id>A14723</ref-id>
            <pubmed-id>10774624</pubmed-id>
            <citation>Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.</citation>
          </article>
          <article>
            <ref-id>A415</ref-id>
            <pubmed-id>19515014</pubmed-id>
            <citation>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</citation>
          </article>
          <article>
            <ref-id>A14734</ref-id>
            <pubmed-id>9890159</pubmed-id>
            <citation>Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53.</citation>
          </article>
          <article>
            <ref-id>A33264</ref-id>
            <pubmed-id>10494454</pubmed-id>
            <citation>von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI: Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.</citation>
          </article>
          <article>
            <ref-id>A183566</ref-id>
            <pubmed-id>10575324</pubmed-id>
            <citation>Olesen OV, Linnet K: Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology. 1999 Dec;59(6):298-309. doi: 10.1159/000028333.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
          <link>
            <ref-id>L8126</ref-id>
            <title>Citalopram FDA label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020822s042,021046s019lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P33261" source="Swiss-Prot">
        <name>Cytochrome P450 2C19</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.</specific-function>
        <gene-name>CYP2C19</gene-name>
        <locus>10q24.1-q24.3</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.42</theoretical-pi>
        <molecular-weight>55930.545</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2621</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M61854</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1328</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P33261</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2CJ_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>CYPIIC17</synonym>
          <synonym>CYPIIC19</synonym>
          <synonym>Cytochrome P450-11A</synonym>
          <synonym>Cytochrome P450-254C</synonym>
          <synonym>Mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020694|Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19)
ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT
GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC
ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG
GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT
CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT
GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG
ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG
GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC
CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC
ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG
AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG
GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT
CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG
CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0002363</id>
      <name>Cytochrome P450 2D6</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14720</ref-id>
            <pubmed-id>8968657</pubmed-id>
            <citation>Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10635" source="Swiss-Prot">
        <name>Cytochrome P450 2D6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</specific-function>
        <gene-name>CYP2D6</gene-name>
        <locus>22q13.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.26</theoretical-pi>
        <molecular-weight>55768.94</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2D6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M20403</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181350</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1329</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10635</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2D6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2DL1</synonym>
          <synonym>CYPIID6</synonym>
          <synonym>Cytochrome P450-DB1</synonym>
          <synonym>Debrisoquine 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004641|Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)
ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG
GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG
CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG
TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG
CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC
CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC
CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC
AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT
TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA
GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT
CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG
CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC
CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG
ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG
AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT
GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC
ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG
CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT
CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT
GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA
TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC
CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC
CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG
CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC
TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>isoquinoline alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular organofluorine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33264</ref-id>
            <pubmed-id>10494454</pubmed-id>
            <citation>von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI: Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F1709</ref-id>
            <title>Citalopram FDA</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/709/original/fda_lalbel_citalopram.pdf?1538411342</url>
          </attachment>
          <attachment>
            <ref-id>F3289</ref-id>
            <title>MedSafe NZ Data Sheet, Citalopram</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/289/original/ArrowCitalopramtab.pdf?1549058792</url>
          </attachment>
        </attachments>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
        <name>Cytochrome P450 1A2</name>
        <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
        <gene-name>CYP1A2</gene-name>
        <locus>15q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.43</theoretical-pi>
        <molecular-weight>58293.76</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2596</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z00036</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYPIA2</synonym>
          <synonym>Cytochrome P(3)450</synonym>
          <synonym>Cytochrome P450 4</synonym>
          <synonym>Cytochrome P450-P3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative deethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="0">
      <id>BE0001032</id>
      <name>P-glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15822</ref-id>
            <pubmed-id>12649369</pubmed-id>
            <citation>Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.</citation>
          </article>
          <article>
            <ref-id>A16168</ref-id>
            <pubmed-id>18215618</pubmed-id>
            <citation>Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. doi: 10.1016/j.neuron.2007.11.017.</citation>
          </article>
          <article>
            <ref-id>A33364</ref-id>
            <pubmed-id>12650738</pubmed-id>
            <citation>Uhr M, Grauer MT: abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res. 2003 May-Jun;37(3):179-85.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
        <name>Multidrug resistance protein 1</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
        <gene-name>ABCB1</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>141477.255</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:40</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MDR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.44</synonym>
          <synonym>ATP-binding cassette sub-family B member 1</synonym>
          <synonym>MDR1</synonym>
          <synonym>P-glycoprotein 1</synonym>
          <synonym>PGY1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G2/M transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stem cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>